Search

Your search keyword '"Arrojo M"' showing total 41 results
Start Over Author "Arrojo M" Database OpenAIRE
41 results on '"Arrojo M"'

1. Cognitive functioning throughout adulthood and illness stages in individuals with psychotic disorders and their unaffected siblings

Author

Velthorst E., Mollon J., Murray R. M., de Haan L., Germeys I. M., Glahn D. C., Arango C., van der Ven E., Di Forti M., Bernardo M., Guloksuz S., Delespaul P., Mezquida G., Amoretti S., Bobes J., Saiz P. A., Garcia-Portilla M. P., Santos J. L., Jimenez-Lopez E., Sanjuan J., Aguilar E. J., Arrojo M., Carracedo A., Lopez G., Gonzalez-Penas J., Parellada M., Atbasoglu C., Saka M. C., Ucok A., Alptekin K., Akdede B., Binbay T., Altinyazar V., Ulas H., Yalincetin B., Gumus-Akay G., Beyaz B. C., Soygur H., Cankurtaran E. S., Kaymak S. U., Maric N. P., Mihaljevic M. M., Petrovic S. A., Mirjanic T., Del-Ben C. M., Ferraro L., Gayer-Anderson C., Jones P. B., Jongsma H. E., Kirkbride J. B., La Cascia C., Lasalvia A., Tosato S., Llorca P. -M., Menezes P. R., Morgan C., Quattrone D., Menchetti M., Selten J. -P., Szoke A., Tarricone I., Tortelli A., McGuire P., Valmaggia L., Kempton M. J., van der Gaag M., Riecher-Rossler A., Bressan R. A., Barrantes-Vidal N., Nelson B., McGorry P., Pantelis C., Krebs M. -O., Ruhrmann S., Sachs G., Rutten B. P. F., van Os J., Alizadeh B. Z., van Amelsvoort T., Bartels-Velthuis A. A., Bruggeman R., van Beveren N. J., Luykx J. J., Cahn W., Simons C. J. P., Kahn R. S., Schirmbeck F., van Winkel R., Calem M., Tognin S., Modinos G., Pisani S., Kraan T. C., van Dam D. S., Burger N., Amminger G. P., Politis A., Goodall J., Borgwardt S., Studerus E., Gadelha A., Brietzke E., Asevedo G., Asevedo E., Zugman A., Dominguez-Martinez T., Monsonet M., Cristobal-Narvaez P., Racioppi A., Kwapil T. R., Kazes M., Daban C., Bourgin J., Gay O., Mam-Lam-Fook C., Nordholm D., Rander L., Krakauer K., Glenthoj L. B., Glenthoj B., Gebhard D., Arnhold J., Klosterkotter J., Lasser I., Winklbaur B., Reichenberg A., Velthorst E., Mollon J., Murray R.M., de Haan L., Germeys I.M., Glahn D.C., Arango C., van der Ven E., Di Forti M., Bernardo M., Guloksuz S., Delespaul P., Mezquida G., Amoretti S., Bobes J., Saiz P.A., Garcia-Portilla M.P., Santos J.L., Jimenez-Lopez E., Sanjuan J., Aguilar E.J., Arrojo M., Carracedo A., Lopez G., Gonzalez-Penas J., Parellada M., Atbasoglu C., Saka M.C., Ucok A., Alptekin K., Akdede B., Binbay T., Altinyazar V., Ulas H., Yalincetin B., Gumus-Akay G., Beyaz B.C., Soygur H., Cankurtaran E.S., Kaymak S.U., Maric N.P., Mihaljevic M.M., Petrovic S.A., Mirjanic T., Del-Ben C.M., Ferraro L., Gayer-Anderson C., Jones P.B., Jongsma H.E., Kirkbride J.B., La Cascia C., Lasalvia A., Tosato S., Llorca P.-M., Menezes P.R., Morgan C., Quattrone D., Menchetti M., Selten J.-P., Szoke A., Tarricone I., Tortelli A., McGuire P., Valmaggia L., Kempton M.J., van der Gaag M., Riecher-Rossler A., Bressan R.A., Barrantes-Vidal N., Nelson B., McGorry P., Pantelis C., Krebs M.-O., Ruhrmann S., Sachs G., Rutten B.P.F., van Os J., Alizadeh B.Z., van Amelsvoort T., Bartels-Velthuis A.A., Bruggeman R., van Beveren N.J., Luykx J.J., Cahn W., Simons C.J.P., Kahn R.S., Schirmbeck F., van Winkel R., Calem M., Tognin S., Modinos G., Pisani S., Kraan T.C., van Dam D.S., Burger N., Amminger G.P., Politis A., Goodall J., Borgwardt S., Studerus E., Gadelha A., Brietzke E., Asevedo G., Asevedo E., Zugman A., Dominguez-Martinez T., Monsonet M., Cristobal-Narvaez P., Racioppi A., Kwapil T.R., Kazes M., Daban C., Bourgin J., Gay O., Mam-Lam-Fook C., Nordholm D., Rander L., Krakauer K., Glenthoj L.B., Glenthoj B., Gebhard D., Arnhold J., Klosterkotter J., Lasser I., Winklbaur B., Reichenberg A., RS: MHeNs - R2 - Mental Health, Psychiatrie & Neuropsychologie, RS: MHeNs - R1 - Cognitive Neuropsychiatry and Clinical Neuroscience, Neurosciences, Psychiatry, Clinical Developmental Psychology, World Health Organization (WHO) Collaborating Center, Life Course Epidemiology (LCE), Groningen Institute for Gastro Intestinal Genetics and Immunology (3GI), Clinical Cognitive Neuropsychiatry Research Program (CCNP), Real World Studies in PharmacoEpidemiology, -Genetics, -Economics and -Therapy (PEGET), Adult Psychiatry, APH - Mental Health, Amsterdam Neuroscience - Complex Trait Genetics, and Amsterdam Neuroscience - Mood, Anxiety, Psychosis, Stress & Sleep

Subjects
0301 basic medicine, validity, medicine.medical_treatment, CHILDHOOD, Neuropsychological Tests, FAMÍLIA, episode, Cognition, 0302 clinical medicine, DEFICITS, Settore MED/48 -Scienze Infermierist. e Tecn. Neuro-Psichiatriche e Riabilitat, Medicine, Cognitive impairment, Psychiatry, Symptom severity, Cannabis use, IMPAIRMENT, ABILITY, Psychiatry and Mental health, Schizophrenia, RELIABILITY, Neuropsychological Test, Life Sciences & Biomedicine, Human, Clinical psychology, Adult, Biochemistry & Molecular Biology, impairment, schizophrenia-patients, ability, GENETIC RISK, Psychotic Disorder, SCHIZOPHRENIA-PATIENTS, 03 medical and health sciences, Cellular and Molecular Neuroscience, SDG 3 - Good Health and Well-being, Settore M-PSI/08 - Psicologia Clinica, Humans, In patient, Cognitive skill, VALIDITY, Antipsychotic, Molecular Biology, Settore MED/25 - Psichiatria, Aged, Cross-Sectional Studie, DECLINE, Science & Technology, reliability, business.industry, Working memory, Siblings, Neurosciences, Diagnostic markers, medicine.disease, Cross-Sectional Studies, 030104 developmental biology, deficits, Psychotic Disorders, PSYCHOSIS, COGNITION, MULTICENTRIC STUDY, Neurosciences & Neurology, business, EPISODE, 030217 neurology & neurosurgery
Abstract

The European Community’s Seventh Framework Programme under grant agreement No. HEALTH-F2-2010-241909 (EUGEI); The Spanish sample was supported by the Spanish Ministry of Science and Innovation, Instituto de Salud Carlos III (SAM16PE07CP1, PI16/02012, PI19/024) (...), Velthorst, E., Mollon, J., Murray, R.M., de Haan, L., Germeys, I.M., Glahn, D.C., Arango, C., van der Ven, E., Di Forti, M., Bernardo, M., Guloksuz, S., Delespaul, P., Mezquida, G., Amoretti, S., Bobes, J., Saiz, P.A., García-Portilla, M.P., Santos, J.L., Jiménez-López, E., Sanjuan, J., Aguilar, E.J., Arrojo, M., Carracedo, A., López, G., González-Peñas, J., Parellada, M., Atbaşoğlu, C., Saka, M.C., Üçok, A., Alptekin, K., Akdede, B., Binbay, T., Altınyazar, V., Ulaş, H., Yalınçetin, B., Gümüş-Akay, G., Beyaz, B.C., Soygür, H., Cankurtaran, E.Ş., Kaymak, S.U., Maric, N.P., Mihaljevic, M.M., Petrovic, S.A., Mirjanic, T., Del-Ben, C.M., Ferraro, L., Gayer-Anderson, C., Jones, P.B., Jongsma, H.E., Kirkbride, J.B., La Cascia, C., Lasalvia, A., Tosato, S., Llorca, P.-M., Menezes, P.R., Morgan, C., Quattrone, D., Menchetti, M., Selten, J.-P., Szöke, A., Tarricone, I., Tortelli, A., McGuire, P., Valmaggia, L., Kempton, M.J., van der Gaag, M., Riecher-Rössler, A., Bressan, R.A., Barrantes-Vidal, N., Nelson, B., McGorry, P., Pantelis, C., Krebs, M.-O., Ruhrmann, S., Sachs, G., Rutten, B.P.F., van Os, J., Alizadeh, B.Z., van Amelsvoort, T., Bartels-Velthuis, A.A., Bruggeman, R., van Beveren, N.J., Luykx, J.J., Cahn, W., Simons, C.J.P., Kahn, R.S., Schirmbeck, F., van Winkel, R., Calem, M., Tognin, S., Modinos, G., Pisani, S., Kraan, T.C., van Dam, D.S., Burger, N., Amminger, G.P., Politis, A., Goodall, J., Borgwardt, S., Studerus, E., Gadelha, A., Brietzke, E., Asevedo, G., Asevedo, E., Zugman, A., Domínguez-Martínez, T., Monsonet, M., Cristóbal-Narváez, P., Racioppi, A., Kwapil, T.R., Kazes, M., Daban, C., Bourgin, J., Gay, O., Mam-Lam-Fook, C., Nordholm, D., Rander, L., Krakauer, K., Glenthøj, L.B., Glenthøj, B., Gebhard, D., Arnhold, J., Klosterkötter, J., Lasser, I., Winklbaur, B., Reichenberg, A., EU-GEI High Risk Study

Published
2021

2. Cannabis use as a potential mediator between childhood adversity and first-episode psychosis: results from the EU-GEI case-control study

Author

Trotta, G, Rodriguez, V, Quattrone, D, Spinazzola, E, Tripoli, G, Gayer-Anderson, C, Freeman, Tp, Jongsma, He, Sideli, L, Aas, M, Stilo, Sa, La Cascia, C, Ferraro, L, La Barbera, D, Lasalvia, A, Tosato, S, Tarricone, I, D'Andrea, G, Tortelli, A, Schurhoff, F, Szoke, A, Pignon, B, Selten, Jp, Velthorst, E, de Haan, L, Llorca, Pm, Menezes, Pr, Del Ben, Cm, Santos, Jl, Arrojo, M, Bobes, J, Sanjuan, J, Bernardo, M, Arango, C, Kirkbride, Jb, Jones, Pb, Richards, A, Rutten, Bp, Van Os, J, Austin-Zimmerman, I, Zk, Li, Morgan, C, Sham, Pc, Vassos, E, Wong, C, Bentall, R, Fisher, Hl, Murray, Rm, Alameda, L, and Di Forti, M

Subjects
trauma, psychotic disorders, childhood experience, mediation, Cannabis use
Published
2023

3. Clinical practice guideline on pharmacological and psychological management of adult patients with depression and a comorbid substance use disorder

Author

Torrens, M, Tirado-Munoz, J, Fonseca, F, Farre, M, Gonzalez-Pinto, A, Arrojo, M, Bernardo, M, Arranz, B, Garriga, M, Saiz, PA, Florez, G, Goikolea, JM, Zorrilla, I, Cunill, R, Castells, X, Becona, E, Lopez, A, and San, L

Subjects
cannabis, Depression, substance use disorder, alcohol, selective serotonin reuptake inhibitors, antidepressants, cocaine, nicotine
Abstract

Co-occurrence of depression and a substance use disorder (SUD) in patients who present dual diagnoses has been long recognized as an important consideration in clinical practice. This review synthesizes the evidence of pharmacological and psychosocial interventions for comorbid depressive disorders and SUDs while providing clinical recommendations about the best interventions to address these patients. The best evidence from randomized controlled trials was used to evaluate treatment options. The strength of recommendations was described using the GRADE approach. Our results suggest that 1) In patients with depression and alcohol consumption, the administration of non-selective serotonin reuptake inhibitor (SSRI) antidepressants instead of SSRI is recommended for improvement of depressive symptoms (strong recommendation). Neither SSRI (strong recommendation) nor non-SSRI (weak recommendation) antidepressants are recommended for reduction in alcohol consumption. 2) In patients with depression and cannabis use, the use of venlafaxine is not recommended (weak recommendation). 3) In patients with depression and cocaine consumption, the use of SSRI antidepressants for improving depressive symptoms (weak recommendation) or to reduce cocaine use is not recommended (strong recommendation). The use of non-SSRI antidepressants is only recommended for improving depressive symptoms (strong recommendation). 4) The administration of bupropion to reduce nicotine consumption is not recommended (strong recommendation). 5) Regarding psychological treatment, in patients with depression and co-occurring alcohol disorder, both pharmacotherapy and cognitive behavioural therapy have positive effects on internalizing symptoms and in reducing alcohol consumption (weak recommendation). Our review suggests the need for more research in this area and for larger, multisite, randomized studies to provide more definite evidence.

Published
2022

4. Clinical practice guideline on pharmacological and psychological management of adult patients with schizophrenia spectrum disorders and a comorbid substance use

Author

Arranz B, Garriga M, Bernardo M, González-Pinto A, Arrojo M, Torrens M, Tirado-Muñoz J, Fonseca F, Sáiz PA, Flórez G, Goikolea JM, Zorrilla I, Cunill R, Castells X, Becoña E, Angeles López Ponce, and San L

Abstract

Although correct diagnosis and management of patients with schizophrenia and a comorbid substance use disorder (SUD) would determine a decrease in morbidity and mortality in these patients, development of efficient therapeutic strategies is still pending. We present recommendations on the pharmacological and psychological management of these patients following the 'PICO' structure (Patient-Intervention-Comparison-Outcomes). Evaluation of the quality of studies and summary of the evidence for each question was performed following the recommendations of the GRADE (Grading of Recommendations, Assessment, Development and Evaluation) working group. Our results suggest: 1) In patients with schizophrenia and cannabis use disorder, it is not possible to recommend one antipsychotic drug over another (between olanzapine, risperidone or haloperidol) for improving psychotic symptoms, reducing cannabis use, or improving pragmatic variables (weak recommendation). Clozapine cannot be recommended to reduce cannabis use (weak recommendation). 2) In patients with schizophrenia and cocaine use disorder we recommend haloperidol over olanzapine to reduce craving (moderate recommendation), and olanzapine over haloperidol to improve motor side effects in these patients (moderate recommendation). 3) In patients with schizophrenia and alcohol use disorder while naltrexone is recommended to reduce alcohol use (in terms of reducing alcohol craving) (weak recommendation), there is insufficient evidence to make any recommendation on the use of adjuvant acamprosate (weak recommendation). 4) In patients with schizophrenia and nicotine use disorder, adjuvant bupropion and varenicline are recommended for reducing nicotine use and nicotine abstinence (strong/moderate recommendation). 5) In patients with schizophrenia and polydrug use disorder, second-generation over first-generation antipsychotic drugs and olanzapine over other second-generation antipsychotics are recommended to improve psychotic symptoms (moderate/weak recommendation).

Published
2022

5. Clinical practice guideline on pharmacological and psychological management of adult patients with attention deficit and hyperactivity disorder and comorbid substance use

Author

Cunill R, Castells X, González-Pinto A, Arrojo M, Bernardo M, Sáiz PA, Florez G, Torrens M, Tirado-Muñoz J, Fonseca F, Arranz B, Garriga M, Goikolea JM, Zorrilla I, Becoña E, Angeles López Ponce, and San L

Subjects
mental disorders, behavioral disciplines and activities
Abstract

Substantial evidence has confirmed the high comorbidity between Attention-Deficit/Hyperactivity Disorder (ADHD) and a substance use disorder (SUD). This review synthesizes the pharmacological and psychosocial interventions conducted in ADHD and SUDs, and provides clinical recommendations using the GRADE approach. Our results suggest: 1) In patients with ADHD and alcohol use, atomoxetine is recommended to reduce ADHD symptoms (weak recommendation) and alcohol craving (weak recommendation). 2) In patients with ADHD and cannabis use disorder, atomoxetine is recommended to improve ADHD symptoms (weak recommendation), not to reduce cannabis use (weak recommendation). 3) In patients with ADHD and cocaine use disorder, methylphenidate is not recommended to improve ADHD symptoms or to reduce cocaine use (weak recommendation). 4) In patients with ADHD and comorbid nicotine use disorder, methylphenidate is recommended to improve ADHD symptoms (weak recommendation). Psychoestimulants, such as methylphenidate or lisdexamfetamine dimesylate, are not recommended to reduce nicotine use (weak recommendation). 5) Regarding patients with ADHD and any SUD, the use of psychostimulants is recommended to improve ADHD symptoms (weak recommendation), not to reduce substance use (weak recommendation) or to improve retention to treatment (strong recommendation). In these patients, the use of atomoxetine is recommended to improve ADHD symptoms (weak recommendation), not to decrease substance use (weak recommendation) or to improve retention to treatment (strong recommendation). Atomoxetine and psychostimulants appear to be safe in patients with any SUD (strong recommendation). Our review suggests the need for more research in this area and for larger, multisite, randomized studies to provide more definite and conclusive evidence.

Published
2022

6. Social disadvantage, linguistic distance, ethnic minority status and first-episode psychosis: results from the EU-GEI case-control study

Author

Jongsma H, Gayer-Anderson C, Tarricone I, Velthorst E, van der Ven E, Quattrone D, di Forti M, Menezes P, Del-Ben C, Arango C, Lasalvia A, Berardi D, La Cascia C, Bobes J, Bernardo M, Sanjuan J, Santos J, Arrojo M, de Haan L, Tortelli A, Szoke A, Murray R, Rutten B, van Os J, Morgan C, Jones P, Kirkbride J, EU-GEI WP2 Group, Jongsma, Hannah E [0000-0001-6346-5903], and Apollo - University of Cambridge Repository

Subjects
Adult, Male, Adolescent, Social Determinants of Health, social disadvantage, Communication Barriers, Black People, Health Status Disparities, Middle Aged, White People, Europe, Young Adult, Psychotic Disorders, Case-Control Studies, Discrimination, Ethnic and Racial Minorities, Ethnicity, Odds Ratio, Schizophrenia, Humans, epidemiology, Female, Gene-Environment Interaction
Abstract

BACKGROUND: Ethnic minority groups in Western countries face an increased risk of psychotic disorders. Causes of this long-standing public health inequality remain poorly understood. We investigated whether social disadvantage, linguistic distance and discrimination contributed to these patterns.; METHODS: We used case-control data from the EUropean network of national schizophrenia networks studying Gene-Environment Interactions (EU-GEI) study, carried out in 16 centres in six countries. We recruited 1130 cases and 1497 population-based controls. Our main outcome measure was first-episode ICD-10 psychotic disorder (F20-F33), and exposures were ethnicity (white majority, black, mixed, Asian, North-African, white minority and other), generational status, social disadvantage, linguistic distance and discrimination. Age, sex, paternal age, cannabis use, childhood trauma and parental history of psychosis were included as a priori confounders. Exposures and confounders were added sequentially to multivariable logistic models, following multiple imputation for missing data.; RESULTS: Participants from any ethnic minority background had crude excess odds of psychosis [odds ratio (OR) 2.03, 95% confidence interval (CI) 1.69-2.43], which remained after adjustment for confounders (OR 1.61, 95% CI 1.31-1.98). This was progressively attenuated following further adjustment for social disadvantage (OR 1.52, 95% CI 1.22-1.89) and linguistic distance (OR 1.22, 95% CI 0.95-1.57), a pattern mirrored in several specific ethnic groups. Linguistic distance and social disadvantage had stronger effects for first- and later-generation groups, respectively.; CONCLUSION: Social disadvantage and linguistic distance, two potential markers of sociocultural exclusion, were associated with increased odds of psychotic disorder, and adjusting for these led to equivocal risk between several ethnic minority groups and the white majority.

Published
2021

7. Examining the association between exposome score for schizophrenia and functioning in schizophrenia, siblings, and healthy controls: results from the EUGEI study

Author

Erzin G, Pries L, van Os J, Fusar-Poli L, Delespaul P, Kenis G, Luykx J, Lin B, Richards A, Akdede B, Binbay T, Altinyazar V, Yalincetin B, Gumus-Akay G, Cihan B, Soygur H, Ulas H, Cankurtaran E, Kaymak S, Mihaljevic M, Andric-Petrovic S, Mirjanic T, Bernardo M, Mezquida G, Amoretti S, Bobes J, Saiz P, Garcia-Portilla M, Sanjuan J, Aguilar E, Santos J, Jimenez-Lopez E, Arrojo M, Carracedo A, Lopez G, Gonzalez-Penas J, Parellada M, Maric N, Atbasoglu C, Ucok A, Alptekin K, Saka M, Arango C, O'Donovan M, Rutten B, Guloksuz S, and Genetic Risk and Outcome of Psychosis (GROUP) investigators

Published
2021

8. Replicated evidence that endophenotypic expression of schizophrenia polygenic risk is greater in healthy siblings of patients compared to controls, suggesting gene-environment interaction. The EUGEI study

Author

van Os J, Pries L, Delespaul P, Kenis G, Luykx J, Lin B, Richards A, Akdede B, Binbay T, Altinyazar V, Yalincetin B, Gumus-Akay G, Cihan B, Soygur H, Ulas H, Cankurtaran E, Kaymak S, Mihaljevic M, Petrovic S, Mirjanic T, Bernardo M, Cabrera B, Bobes J, Saiz P, Garcia-Portilla M, Sanjuan J, Aguilar E, Santos J, Jimenez-Lopez E, Arrojo M, Carracedo A, Lopez G, Gonzalez-Penas J, Parellada M, Maric N, Atbasoglu C, Ucok A, Alptekin K, Saka M, Arango C, O'Donovan M, Rutten B, Guloksuz S, and Genetic Risk Outcome Investigators

Subjects
schizophrenia, Cognition, schizotypy, genetics
Abstract

Background First-degree relatives of patients with psychotic disorder have higher levels of polygenic risk (PRS) for schizophrenia and higher levels of intermediate phenotypes. Methods We conducted, using two different samples for discovery (n= 336 controls and 649 siblings of patients with psychotic disorder) and replication (n= 1208 controls and 1106 siblings), an analysis of association between PRS on the one hand and psychopathological and cognitive intermediate phenotypes of schizophrenia on the other in a sample at average genetic risk (healthy controls) and a sample at higher than average risk (healthy siblings of patients). Two subthreshold psychosis phenotypes, as well as a standardised measure of cognitive ability, based on a short version of the WAIS-III short form, were used. In addition, a measure of jumping to conclusion bias (replication sample only) was tested for association with PRS. Results In both discovery and replication sample, evidence for an association between PRS and subthreshold psychosis phenotypes was observed in the relatives of patients, whereas in the controls no association was observed. Jumping to conclusion bias was similarly only associated with PRS in the sibling group. Cognitive ability was weakly negatively and non-significantly associated with PRS in both the sibling and the control group. Conclusions The degree of endophenotypic expression of schizophrenia polygenic risk depends on having a sibling with psychotic disorder, suggestive of underlying gene-environment interaction. Cognitive biases may better index genetic risk of disorder than traditional measures of neurocognition, which instead may reflect the population distribution of cognitive ability impacting the prognosis of psychotic disorder.

Published
2020

9. Examining the independent and joint effects of genomic and exposomic liabilities for schizophrenia across the psychosis spectrum

Author

Pries L, Dal Ferro G, van Os J, Delespaul P, Kenis G, Lin B, Luykx J, Richards A, Akdede B, Binbay T, Altinyazar V, Yalincetin B, Gumus-Akay G, Cihan B, Soygur H, Ulas H, Cankurtaran E, Kaymak S, Mihaljevic M, Petrovic S, Mirjanic T, Bernardo M, Mezquida G, Amoretti S, Bobes J, Saiz P, Garcia-Portilla M, Sanjuan J, Aguilar E, Santos J, Jimenez-Lopez E, Arrojo M, Carracedo A, Lopez G, Gonzalez-Penas J, Parellada M, Maric N, Atbasoglu C, Ucok A, Alptekin K, Saka M, Arango C, O'Donovan M, Tosato S, Rutten B, Guloksuz S, and Genetic Risk Outcome Psychosis GRP

Subjects
schizotypy, genetics, psychosis, Environment
Abstract

Aims Psychosis spectrum disorder has a complex pathoetiology characterised by interacting environmental and genetic vulnerabilities. The present study aims to investigate the role of gene-environment interaction using aggregate scores of genetic (polygenic risk score for schizophrenia (PRS-SCZ)) and environment liability for schizophrenia (exposome score for schizophrenia (ES-SCZ)) across the psychosis continuum. Methods The sample consisted of 1699 patients, 1753 unaffected siblings, and 1542 healthy comparison participants. The Structured Interview for Schizotypy-Revised (SIS-R) was administered to analyse scores of total, positive, and negative schizotypy in siblings and healthy comparison participants. The PRS-SCZ was trained using the Psychiatric Genomics Consortiums results and the ES-SCZ was calculated guided by the approach validated in a previous report in the current data set. Regression models were applied to test the independent and joint effects of PRS-SCZ and ES-SCZ (adjusted for age, sex, and ancestry using 10 principal components). Results Both genetic and environmental vulnerability were associated with case-control status. Furthermore, there was evidence for additive interaction between binary modes of PRS-SCZ and ES-SCZ (above 75% of the control distribution) increasing the odds for schizophrenia spectrum diagnosis (relative excess risk due to interaction = 6.79, [95% confidential interval (CI) 3.32, 10.26], p < 0.001). Sensitivity analyses using continuous PRS-SCZ and ES-SCZ confirmed gene-environment interaction (relative excess risk due to interaction = 1.80 [95% CI 1.01, 3.32], p = 0.004). In siblings and healthy comparison participants, PRS-SCZ and ES-SCZ were associated with all SIS-R dimensions and evidence was found for an interaction between PRS-SCZ and ES-SCZ on the total (B = 0.006 [95% CI 0.003, 0.009], p < 0.001), positive (B = 0.006 [95% CI, 0.002, 0.009], p = 0.002), and negative (B = 0.006, [95% CI 0.004, 0.009], p < 0.001) schizotypy dimensions. Conclusions The interplay between exposome load and schizophrenia genetic liability contributing to psychosis across the spectrum of expression provide further empirical support to the notion of aetiological continuity underlying an extended psychosis phenotype.

Published
2020

10. The EUropean Network of National Schizophrenia Networks Studying Gene-Environment Interactions (EU-GEI): Incidence and First-Episode Case-Control Programme

Author

Gayer-Anderson C, Jongsma H, Di Forti M, Quattrone D, Velthorst E, de Haan L, Selten J, Sz?ke A, Llorca P, Tortelli A, Arango C, Bobes J, Bernardo M, Sanju?n J, Santos J, Arrojo M, Parellada M, Tarricone I, Berardi D, Ruggeri M, Lasalvia A, Ferraro L, La Cascia C, La Barbera D, Menezes P, Del-Ben C, Rutten B, van Os J, Jones P, Murray R, Kirkbride J, Morgan C, and EU-GEI WP2 Grp

Subjects
Environment-environment interactions, Incidence, Gene-environment interactions, Case-control, First-episode psychosis, EU-GEI
Abstract

Purpose The EUropean Network of National Schizophrenia Networks Studying Gene-Environment Interactions (EU-GEI) study contains an unparalleled wealth of comprehensive data that allows for testing hypotheses about (1) variations in incidence within and between countries, including by urbanicity and minority ethnic groups; and (2) the role of multiple environmental and genetic risk factors, and their interactions, in the development of psychotic disorders. Methods Between 2010 and 2015, we identified 2774 incident cases of psychotic disorders during 12.9 million person-years at risk, across 17 sites in 6 countries (UK, The Netherlands, France, Spain, Italy, and Brazil). Of the 2774 incident cases, 1130 cases were assessed in detail and form the case sample for case-control analyses. Across all sites, 1497 controls were recruited and assessed. We collected data on an extensive range of exposures and outcomes, including demographic, clinical (e.g. premorbid adjustment), social (e.g. childhood and adult adversity, cannabis use, migration, discrimination), cognitive (e.g. IQ, facial affect processing, attributional biases), and biological (DNA via blood sample/cheek swab). We describe the methodology of the study and some descriptive results, including representativeness of the cohort. Conclusions This resource constitutes the largest and most extensive incidence and case-control study of psychosis ever conducted.

Published
2020

11. Premorbid Adjustment and IQ in Patients With First-Episode Psychosis: A Multisite Case-Control Study of Their Relationship With Cannabis Use

Author

Ferraro L, La Cascia C, Quattrone D, Sideli L, Matranga D, Capuccio V, Tripoli G, Gayer-Anderson C, Morgan C, Sami M, Sham P, de Haan L, Velthorst E, Jongsma H, Kirkbride J, Rutten B, Richards A, Roldan L, Arango C, Bernardo M, Bobes J, Sanjuan J, Santos J, Arrojo M, Tarricone I, Tortelli A, Szoke A, Del-Ben C, Selten J, Lynskey M, Jones P, Van Os J, La Barbera D, Murray R, Di Forti M, WP2 EU-GEI GROUP, Jones, Peter [0000-0002-0387-880X], and Apollo - University of Cambridge Repository

Subjects
cognition, Adult, Male, education, Adolescent, Intelligence, preillness, Comorbidity, Middle Aged, schizophrenia, sociability, Psychosocial Functioning, Young Adult, Psychotic Disorders, Case-Control Studies, Humans, Female, Marijuana Use, marijuana, Social Adjustment
Abstract

Psychotic patients with a lifetime history of cannabis use generally show better cognitive functioning than other psychotic patients. Some authors suggest that cannabis-using patients may have been less cognitively impaired and less socially withdrawn in their premorbid life. Using a dataset comprising 948 patients with first-episode psychosis (FEP) and 1313 population controls across 6 countries, we examined the extent to which IQ and both early academic (Academic Factor [AF]) and social adjustment (Social Factor [SF]) are related to the lifetime frequency of cannabis use in both patients and controls. We expected a higher IQ and a better premorbid social adjustment in psychotic patients who had ever used cannabis compared to patients without any history of use. We did not expect such differences in controls. In both patients and controls, IQ was 3 points higher among occasional-users than in never-users (mean difference [Mdiff] = 2.9, 95% CI = [1.2, 4.7]). Both cases and control daily-users had lower AF compared to occasional (Mdiff = -0.3, 95% CI = [-0.5; -0.2]) and never-users (Mdiff = -0.4, 95% CI = [-0.6; -0.2]). Finally, patient occasional (Mdiff = 0.3, 95% CI = [0.1; 0.5]) and daily-users (Mdiff = 0.4, 95% CI = [0.2; 0.6]) had better SF than their never-using counterparts. This difference was not present in controls (Fgroup*frequency(2, 2205) = 4.995, P = .007). Our findings suggest that the better premorbid social functioning of FEP with a history of cannabis use may have contributed to their likelihood to begin using cannabis, exposing them to its reported risk-increasing effects for Psychotic Disorders. © The Author(s) 2019. Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center.All rights reserved. For permissions, please email: journals.permissions@oup.com.

Published
2019
Full Text
View/download PDF

12. Estimating Exposome Score for Schizophrenia Using Predictive Modeling Approach in Two Independent Samples: The Results From the EUGEI Study

Author

Pries L, Lage-Castellanos A, Delespaul P, Kenis G, Luykx J, Lin B, Richards A, Akdede B, Binbay T, Altinyazar V, Yalincetin B, Gumus-Akay G, Cihan B, Soygur H, Ulas H, Cankurtaran E, Kaymak S, Mihaljevic M, Petrovic S, Mirjanic T, Bernardo M, Cabrera B, Bobes J, Saiz P, Garcia-Portilla M, Sanjuan J, Aguilar E, Santos J, Jimenez-Lopez E, Arrojo M, Carracedo A, Lopez G, Gonzalez-Penas J, Parellada M, Maric N, Atbasoglu C, Ucok A, Alptekin K, Saka M, Arango C, O'Donovan M, Rutten B, van Os J, Guloksuz S, Alizadeh B, van Amelsvoort T, Bruggeman R, Cahnm W, de Haan L, van Winkel R, and Genetic Risk Outcome Psychosis Grp

Subjects
schizophrenia, cannabis, machine learning, childhood trauma, psychosis, hearing impairment, risk score, predictive modeling, environment, winter birth
Abstract

Exposures constitute a dense network of the environment: exposome. Here, we argue for embracing the exposome paradigm to investigate the sum of nongenetic "risk" and show how predictive modeling approaches can be used to construct an exposome score (ES; an aggregated score of exposures) for schizophrenia. The training dataset consisted of patients with schizophrenia and controls, whereas the independent validation dataset consisted of patients, their unaffected siblings, and controls. Binary exposures were cannabis use, hearing impairment, winter birth, bullying, and emotional, physical, and sexual abuse along with physical and emotional neglect. We applied logistic regression (LR), Gaussian Naive Bayes (GNB), the least absolute shrinkage and selection operator (LASSO), and Ridge penalized classification models to the training dataset. ESs, the sum of weighted exposures based on coefficients from each model, were calculated in the validation dataset. In addition, we estimated ES based on meta-analyses and a simple sum score of exposures. Accuracy, sensitivity, specificity, area under the receiver operating characteristic, and Nagelkerke's R-2 were compared. The ESMeta-analyses performed the worst, whereas the sum score and the ESGNB were worse than the ESLR that performed similar to the ESLASSO and ESRIDGE. The ESLR distinguished patients from controls (odds ratio [OR] = 1.94, P < .001), patients from siblings (OR = 1.58, P < .001), and siblings from controls (OR = 1.21, P= .001). An increase in ESLR was associated with a gradient increase of schizophrenia risk. In reference to the remaining fractions, the ESLR at top 30%, 20%, and 10% of the control distribution yielded ORs of 3.72, 3.74, and 4.77, respectively. Our findings demonstrate that predictive modeling approaches can be harnessed to evaluate the exposome.

Published
2019

13. Examining the independent and joint effects of molecular genetic liability and environmental exposures in schizophrenia: results from the EUGEI study

Author

Guloksuz S, Pries L, Delespaul P, Kenis G, Luykx J, Lin B, Richards A, Akdede B, Binbay T, Altinyazar V, Yalincetin B, Gumus-Akay G, Cihan B, Soygur H, Ulas H, Cankurtaran E, Kaymak S, Mihaljevic M, Petrovic S, Mirjanic T, Bernardo M, Cabrera B, Bobes J, Saiz P, Garcia-Portilla M, Sanjuan J, Aguilar E, Santos J, Jimenez-Lopez E, Arrojo M, Carracedo A, Lopez G, Gonzalez-Penas J, Parellada M, Maric N, Atbasoglu C, Ucok A, Alptekin K, Saka M, Arango C, O'Donovan M, Rutten B, van Os J, Alizadeh B, van Amelsvoort T, van Beveren N, Bruggeman R, Cahn W, de Haan L, Myin-Germeys I, van Winkel R, and Genetic Risk Outcome Psychosis

Published
2019

14. Treated Incidence of Psychotic Disorders in the Multinational EU-GEI Study

Author

Jongsma HE, Gayer-Anderson C, Lasalvia A, Quattrone D, Mulè A, Szöke A, Selten JP, Turner C, Arango C, Tarricone I, Berardi D, Tortelli A, Llorca PM, de Haan L, Bobes J, Bernardo M, Sanjuán J, Santos JL, Arrojo M, Del-Ben CM, Menezes PR, Velthorst E, Murray RM, Rutten BP, Jones PB, van Os J, Morgan C, Kirkbride JB, and European Network of National Schizophrenia Networks Studying Gene-Environment In

Published
2018

15. First-time admissions for opioid treatment: cross-sectional and descriptive study of new opioid users seeking treatment

Author

Flórez G, López-Durán A, Triñanes Y, Osorio J, Fraga J, Fernández JM, Becoña E, and Arrojo M

Subjects
Neurosciences. Biological psychiatry. Neuropsychiatry, Neurology. Diseases of the nervous system, RC346-429, RC321-571
Abstract

Gerardo Flórez,1,2 Ana López-Durán,3 Yolanda Triñanes,4 Jesús Osorio,5 Jaime Fraga,5 José Manuel Fernández,5 Elisardo Becoña,3 Manuel Arrojo5 1Addictive Disorders Assistance Unit, Complejo Hospitalario, Ourense, Spain; 2Center for Biomedical Research in Mental Health (CIBERSAM), Oviedo, Spain; 3Department of Clinical Psychology and Psychobiology, University of Santiago de Compostela, Spain; 4Galician Agency for Health Technology Assessment, Directorate General for Innovation and Management of Public Health, Galicia, Spain; 5Directorate General of Health Assistance, Galician Health Service, Galicia, Spain Background: The purpose of this study was to gain an understanding of the profiles of the new treatment demands posed by opioid addicts between 2005 and 2010 at the addictive disorders assistance units in Galicia, Spain. Methods: A cluster analysis was performed using data from 1,655 treatment entrants. Clusters were constructed using sociodemographic and medicolegal variables. A cluster analysis was also conducted according to age. Once clusters were defined, their association with the following variables was analyzed: age at first use of opioids, years of use, frequency of opioid use in the previous month, psychiatric treatment, cocaine use, existence of a drug-dependent partner, and source of referral. Results: Four clusters were obtained in the main analysis. Cluster 1 (34.01%) consisted of young males, cluster 2 (16.19%) consisted of not-so-young males, cluster 3 (32.62%) consisted mainly of older males and a small group of females, and cluster 4 (17.18%) was made up entirely of women. With regard to age-related clusters, two clusters were obtained in those under the age of 30 years: cluster 1 (73%) without medicolegal complications and cluster 2 (27%) with medicolegal complications. For those over the age of 30 years, two clusters were obtained: cluster 1 (53.92%) with hardly any medicolegal complications and cluster 2 (46.08%) with medicolegal complications. Conclusion: Cluster analysis suggests that there have been no substantial changes in variables indicating greater severity in this new group of patients. Women are likely to seek help earlier, which reduces their duration of opioid use. The younger the patient, the shorter the duration of opioid use and the greater the likelihood of cessation of intravenous use. Public health systems should use a two-pronged treatment strategy of short but intense cessation therapies for women and younger treatment entrants and longer maintenance and replacement therapies for older treatment entrants with more psychosocial and medical complications. Keywords: opioid dependence, cluster analysis, treatment-seeking, sex, age

Published
2015

16. Effectiveness, efficiency and efficacy in the multidimensional treatment of schizophrenia: Rethinking project

Author

Crespo-Facorro B, Bernardo M, Argimon J, Arrojo M, Bravo-Ortiz M, Cabrera-Cifuentes A, Carretero-Roman J, Franco-Martin M, Garcia-Portilla P, Haro J, Olivares J, Penades R, del Pino-Montes J, Sanjuan J, and Arang C

Subjects
Conciencia de enfermedad, Adherence, Síntomas negativos, Antipsychotics, Negative symptoms, Antipsicóticos, Insight, Psychosis, Adherencia
Abstract

Schizophrenia is a clinically heterogeneous syndrome affecting multiple dimensions of patients' life. Therefore, its treatment might require a multidimensional approach that should take into account the efficacy (the ability of an intervention to get the desired result under ideal conditions), the effectiveness (the degree to which the intended effect is obtained under routine clinical practice conditions or settings) and the efficiency (value of the intervention as relative to its cost to the individual or society) of any therapeutic intervention. In a first step of the process, a group of 90 national experts from different areas of health-care and with a multidimensional and multidisciplinary perspective of the disease, defined the concepts of efficacy, effectiveness and efficiency of established therapeutic interventions within 7 key dimensions of the illness: symptomatology; comorbidity; relapse and adherence; insight and subjective experience; cognition; quality of life, autonomy and functional capacity; and social inclusion and associated factors. The main conclusions and recommendations of this stage of the work are presented herein.

Published
2017

17. Common variant at 16p11.2 conferring risk of psychosis

Author

Steinberg S, de Jong S, Mattheisen M, Costas J, Demontis D, Jamain S, Pietilxe4inen OP, Lin K, Papiol S, Huttenlocher J, Sigurdsson E, Vassos E, Giegling I, Breuer R, Fraser G, Walker N, Melle I, Djurovic S, Agartz I, Tuulio-Henriksson A, Suvisaari J, Lxf6nnqvist J, Paunio T, Olsen L, Hansen T, Ingason A, Pirinen M, Strengman E, GROUP, Hougaard DM, Orntoft T, Didriksen M, Hollegaard MV, Nordentoft M, Abramova L, Kaleda V, Arrojo M, Sanjuxe1n J, Arango C, Etain B, Bellivier F, Mxe9ary A, Schxfcrhoff F, Szoke A, Ribols, Steinberg S, de Jong S, Mattheisen M, Costas J, Demontis D, Jamain S, Pietilxe4inen OP, Lin K, Papiol S, Huttenlocher J, Sigurdsson E, Vassos E, Giegling I, Breuer R, Fraser G, Walker N, Melle I, Djurovic S, Agartz I, Tuulio-Henriksson A, Suvisaari J, Lxf6nnqvist J, Paunio T, Olsen L, Hansen T, Ingason A, Pirinen M, Strengman E, GROUP, Hougaard DM, Orntoft T, Didriksen M, Hollegaard MV, Nordentoft M, Abramova L, Kaleda V, Arrojo M, Sanjuxe1n J, Arango C, Etain B, Bellivier F, Mxe9ary A, Schxfcrhoff F, Szoke A, and Ribols

Published
2014

18. L’università dell’Utopia. La Statale di Milano negli anni Settanta

Author

Coen Porosini, A., Dionigi, R., Generali, D., Botta, M., Capanna, M., Bellini, R., Baldini, F., Carrozzini, G., Veneziano, R., Martignoni, G. M., Giannitrapani, P., Vedibene, M., Brebbia, G., Meazza, C., Petitot, J., Sini, C., Bianca, M., Broggini, G., Cambria, F., Rodríguez, R. A., Fabbrichesi, R., Handjaras, L., Maiorca, B., Biuso, A. G., Agazzi, E., Heinzmann, G., Coliva, A., Gonzalez, W. J., Arrojo, M. J., Coniglione, F., Negro, M., Chiffi, D., Sabatini, N., Schiavio, F., Taramelli, R., Lenk, H., Maring, M., Cambi, F., Buzzoni, M., Galuzzi, M., Quaranta, M., Renzi, E., Ferri, M. B., Paladini, A., Giannì, I., Scaramuzza, G., Dino, O., DALLA VIGNA, PIERRE ALESSANDRO, Paganini, G., Galli, S. B., Pozzi, P., Kemp, P., Lazzari, M., Marinotti, A., Colonnello, P., Piccari, P., Quarta, A., Vinti, C., Micheli, G., Bazhanov, V. A., Panza, M., Cimino, G., Luzzini, F., Vaccari, E., Wolenski, J., Rossi, A., Bertagna, G., Bartolini, R., Tussi, T., Scolozzi, E., Hagström, E., Ponzellini, V., Patti, A., Barile, S., Veca, S., Frascanetti Brondino, Y., Visconti, K., Orecchia, A. M., Sandrini, M. G., Dobner, C., Moccia, N., Brondino, M., Velázquez, L., Brondino, L., Papi, F., Brissa, E., de Paoli, M., Riccobono, M. G., Santi, G., Pasetti, C., and Martignoni, G.

Published
2015

19. Common variant at 16p11.2 conferring risk of psychosis

Author

Steinberg, S., de Jong, S., Sigurdsson, E., Murray, R., Corvin, A., Gill, M., Morris, D., O'Neill, F. A., Kendler, K., Riley, B., 2, Wellcome Trust Case Control Consortium, Craddock, N., Owen, M. J., Vassos, E., O'Donovan, M. C., Thorsteinsdottir, U., Kong, A., Ehrenreich, H., Carracedo, A., Golimbet, V., Andreassen, O. A., Børglum, A. D., Mors, O., Mortensen, P. B., Giegling, I., Werge, T., Ophoff, R. A., Nöthen, M. M., Rietschel, M., Cichon, S., Ruggeri, M., Tosato, S., Palotie, A., St Clair, D., Rujescu, D., Breuer, R., Collier, D. A., Stefansson, H., Stefansson, K., Donnelly, Peter, Barroso, Ines, Blackwell, Jenefer M, Bramon, Elvira, Brown, Matthew A, Casas, Juan P, Corvin, Aiden, Fraser, G., Deloukas, Panos, Duncanson, Audrey, Jankowski, Janusz, Markus, Hugh S, Mathew, Christopher G, Palmer, Colin N A, Plomin, Robert, Rautanen, Anna, Sawcer, Stephen J, Trembath, Richard C, Walker, N., Viswanathan, Ananth C, Wood, Nicholas W, Spencer, Chris C A, Band, Gavin, Bellenguez, Céline, Freeman, Colin, Hellenthal, Garrett, Giannoulatou, Eleni, Pirinen, Matti, Pearson, Richard, Melle, I., Strange, Amy, Su, Zhan, Vukcevic, Damjan, Langford, Cordelia, Hunt, Sarah E, Edkins, Sarah, Gwilliam, Rhian, Blackburn, Hannah, Djurovic, S., Bumpstead, Suzannah J, Dronov, Serge, Gillman, Matthew, Gray, Emma, Hammond, Naomi, Jayakumar, Alagurevathi, McCann, Owen T, Liddle, Jennifer, Potter, Simon C, Ravindrarajah, Radhi, Agartz, I., Ricketts, Michelle, Waller, Matthew, Weston, Paul, Widaa, Sara, Whittaker, Pamela, Tuulio-Henriksson, A., Mattheisen, M., Suvisaari, J., Lönnqvist, J., Paunio, T., Olsen, L., Hansen, T., Ingason, A., Pirinen, M., Strengman, E., GROUP, Hougaard, D. M., Costas, J., Orntoft, T., Didriksen, M., Hollegaard, M. V., Nordentoft, M., Abramova, L., Kaleda, V., Arrojo, M., Sanjuán, J., Arango, C., Etain, B., Demontis, D., Bellivier, F., Méary, A., Schürhoff, F., Szoke, A., Ribolsi, M., Magni, V., Siracusano, A., Sperling, S., Rossner, M., Christiansen, C., Jamain, S., Kiemeney, L. A., Franke, B., van den Berg, L. H., Veldink, J., Curran, S., Bolton, P., Poot, M., Staal, W., Rehnstrom, K., Kilpinen, H., Pietiläinen, O. P. H., Freitag, C. M., Meyer, J., Magnusson, P., Saemundsen, E., Martsenkovsky, I., Bikshaieva, I., Martsenkovska, I., Vashchenko, O., Raleva, M., Paketchieva, K., Lin, K., Stefanovski, B., Durmishi, N., Pejovic Milovancevic, M., Lecic Tosevski, D., Silagadze, T., Naneishvili, N., Mikeladze, N., Surguladze, S., Vincent, J. B., Farmer, A., Papiol, S., Mitchell, P. B., Wright, A., Schofield, P. R., Fullerton, J. M., Montgomery, G. W., Martin, N. G., Rubino, I. A., van Winkel, R., Kenis, G., De Hert, M., Huttenlocher, J., Réthelyi, J. M., Bitter, I., Terenius, L., Jönsson, E. G., Bakker, S., van Os, J., Jablensky, A., Leboyer, M., Bramon, E., Powell, J., deCODE Genet, IS-101 Reykjavik, Iceland Univ Calif Los Angeles, Ctr Neurobehav Genet, Los Angeles, CA USA Harvard Univ, Brigham & Womens Hosp, Sch Med, Channing Div Network Med, Boston, MA 02115 USA Univ Bonn, Inst Genom Math, Bonn, Germany Univ Bonn, Dept Genom, Life & Brain Ctr, Bonn, Germany CHUS, Galician Fdn Genom Med SERGAS, Santiago De Compostela, Spain Aarhus Univ, Dept Biomed, Aarhus, Denmark Aarhus Univ, iSEQ, Ctr Integrat Sequencing, Aarhus, Denmark Lundbeck Fdn Initiat Integrat Psychiat Res, iPSYCH, Aarhus, Denmark Fdn FondaMental, Creteil, France Hop Henri Mondor, INSERM, U955, F-94010 Creteil, France Univ Helsinki, Inst Mol Med Finland FIMM, Helsinki, Finland Inst Hlth & Welf, Publ Hlth Genom Unit, Helsinki, Finland Wellcome Trust Sanger Inst, Cambridge, England South London & Maudsley NHS Fdn Trust, NIHR Biomed Res Ctr Mental Hlth, Dept Neurosci, London, England Kings Coll London, London, England DFG Res Ctr Mol Physiol Brain CMPB, Gottingen, Germany Max Planck Inst Expt Med, Div Clin Neurosci, D-37075 Gottingen, Germany Univ Tubingen, Inst Human Genet, Dept Med Genet, Tubingen, Germany Natl Univ Hosp Reykjavik, Dept Psychiat, Reykjavik, Iceland Univ Iceland, Sch Med, Reykjavik, Iceland Kings Coll London, Inst Psychiat, Social Genet & Dev Psychiat Res Ctr, London, England Univ Munich, Dept Psychiat, Div Mol & Clin Neurobiol, D-80539 Munich, Germany Heidelberg Univ, Cent Inst Mental Hlth, Dept Genet Epidemiol Psychiat, Mannheim, Germany Univ Aberdeen, Dept Mental Hlth, Royal Cornhill Hosp, Aberdeen, Scotland Ravenscraig Hosp, Greenock, Scotland [Univ Oslo, Inst Clin Med, KG Jebsen Ctr Psychosis Res, Div Mental Hlth & Addict,Oslo Univ Hosp, Oslo, Norway Natl Inst Hlth & Welf, Dept Mental Hlth & Subst Abuse Serv, Helsinki, Finland Univ Helsinki, Dept Psychiat, SF-00180 Helsinki, Finland Univ Helsinki, Cent Hosp, Helsinki, Finland Natl Inst Hlth & Welf THL, Publ Hlth Genom Unit, Helsinki, Finland Univ Copenhagen, Mental Hlth Ctr Sct Hans, Inst Biol Psychiat, Roskilde, Denmark Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford, England Univ Med Ctr Utrecht, Dept Med Genet, Utrecht, Netherlands Statens Serum Inst, Dept Clin Biochem Immunol & Genet, Sect Neonatal Screening & Hormones, DK-2300 Copenhagen, Denmark Aarhus Univ Hosp, Dept Mol Med, DK-8000 Aarhus, Denmark H Lundbeck & Co AS, Synapt Transmiss, Copenhagen, Denmark Copenhagen Univ Hosp, Psychiat Ctr Copenhagen, Copenhagen, Denmark Russian Acad Med Sci, Mental Hlth Res Ctr, Moscow 109801, Russia CHUS, Serv Psychiat, Santiago De Compostela, Spain Univ Valencia, Network Ctr Biomed Res Mental Hlth CIBERSAM, Unit Psychiat, Fac Med, Valencia, Spain Univ Complutense, Hosp Gen Univ Gregorio Maranon, IiSGM, CIBERSAM, E-28040 Madrid, Spain Hop H Mondor A Chenevier, AP HP, Creteil, France Univ Paris Est, Fac Med, Creteil, France Univ Roma Tor Vergata, Dept Neurosci, Sect Psychiat, Rome, Italy Max Planck Inst Expt Med, Dept Neurogenet, D-37075 Gottingen, Germany Nord Biosci, Herlev, Denmark Radboud Univ Nijmegen, Med Ctr, Dept Epidemiol & Biostat, NL-6525 ED Nijmegen, Netherlands Radboud Univ Nijmegen, Med Ctr, Dept Urol, NL-6525 ED Nijmegen, Netherlands Radboud Univ Nijmegen, Med Ctr, Dept Human Genet, NL-6525 ED Nijmegen, Netherlands Radboud Univ Nijmegen, Med Ctr, Dept Psychiat, Donders Inst Brain Cognit & Behav, NL-6525 ED Nijmegen, Netherlands Univ Med Ctr, Rudolf Magnus Inst Neurosci, Dept Neurol, Utrecht, Netherlands Kings Coll London, Inst Psychiat, Dept Child & Adolescent Psychiat, London, England Radboud Univ Nijmegen, Dept Cognit Neurosci, NL-6525 ED Nijmegen, Netherlands Goethe Univ Frankfurt, Dept Child & Adolescent Psychiat Psychosomat & Ps, D-60054 Frankfurt, Germany Univ Trier, Dept Neurobehav Genet, Trier, Germany Natl Univ Hosp Reykjavik, Dept Child & Adolescent Psychiat, Reykjavik, Iceland State Diagnost & Counseling Ctr, Kopavogur, Iceland Ukrainian Res Inst Social Forens Psychiat & Drug, Dept Child Adolescent Psychiat & Med Social Rehab, Kiev, Ukraine Univ Skopje, Dept Child & Adolescent Psychiat, Skopje, Macedonia Inst Mental Hlth, Belgrade, Serbia Univ Belgrade, Fac Med, Belgrade, Serbia Tbilisi State Med Univ TSMU, Dept Psychiat & Drug Addict, Tbilisi, Rep of Georgia Ilia State Univ, Social & Affect Neurosci Lab, Tbilisi, Rep of Georgia Ctr Addict & Mental Hlth CAMH, Mol Neuropsychiat & Dev Lab, Toronto, ON, Canada Prince Wales Hosp, Black Dog Inst, Randwick, NSW 2031, Australia Univ New S Wales, Sch Psychiat, Sydney, NSW, Australia Neurosci Res Australia, Sydney, NSW, Australia Univ New S Wales, Sch Med Sci, Sydney, NSW, Australia Queensland Inst Med Res, Brisbane, Qld 4006, Australia Catholic Univ Louvain, Univ Psychiat Ctr, Kortenberg, Belgium Maastricht Univ, European Grad Sch Neurosci EURON,Med Ctr, Sch Mental Hlth & Neurosci,Dept Psychiat & Psycho, South Limburg Mental Hlth Res & Teaching Network, Maastricht, Netherlands Semmelweis Univ, Dept Psychiat & Psychotherapy, H-1085 Budapest, Hungary Karolinska Hosp & Inst, HUBIN Project, Dept Clin Neurosci, Stockholm, Sweden Univ Med Ctr, Rudolf Magnus Inst Neurosci, Dept Psychiat, Utrecht, Netherlands Maastricht Univ, Dept Psychiat, Med Ctr, Maastricht, Netherlands Univ Western Australia, Graylands Hosp, CCRN, Perth, WA 6009, Australia UCL, Mental Hlth Sci Unit, London, England UCL, Inst Cognit Neurosci, London, England South London & Maudsley NHS Fdn Trust, NIHR Biomed Res Ctr Mental Hlth, Dept Psychosis Studies, London, England Trinity Coll Dublin, Sch Med, Neuropsychiat Genet Res Grp, Dublin, Ireland Queens Univ Belfast, Dept Psychiat, Belfast, Antrim, North Ireland Virginia Commonwealth Univ, Dept Human Genet, Richmond, VA USA Virginia Commonwealth Univ, Virginia Inst Psychiat & Behav Genet, Richmond, VA USA Virginia Commonwealth Univ, Dept Psychiat, Richmond, VA USA Cardiff Univ, Sch Med, Inst Psychol Med & Clin Neurosci, MRC Ctr Neuropsychiat Genet & Genom, Cardiff CF10 3AX, S Glam, Wales Univ Santiago de Compostela, Biomed Network Res Ctr Rare Dis CIBERER, Galician Fdn Genom Med, Genom Med Grp, Santiago De Compostela, Spain Aarhus Univ Hosp, Ctr Psychiat Res, Risskov, Denmark Aarhus Univ, Natl Ctr Register Based Res, Aarhus, Denmark German Ctr Neurodegenerat Disorders DZNE, Bonn, Germany Univ Bonn, Inst Human Genet, Bonn, Germany Inst Neurosci & Med INM 1, Julich, Germany Univ Verona, Sect Psychiat, I-37100 Verona, Italy Broad Inst MIT & Harvard, Program Med & Populat Genet & Genet Anal Platform, Cambridge, MA USA Univ Helsinki, Dept Med Genet, Helsinki, Finland Univ Cent Hosp, Helsinki, Finland Univ Halle Wittenberg, Dept Psychiat, D-06108 Halle, Germany Eli Lilly & Co Ltd, Erl Wood Manor, Windlesham, Surrey, England, Psychiatrie & Neuropsychologie, MUMC+: MA Psychiatrie (3), MUMC+: Hersen en Zenuw Centrum (3), and RS: MHeNs - R2 - Mental Health

Subjects
Oncology, Male, association, Bipolar disorder, cross-disorder, schizophrenia, 1p11.2, Bipolar Disorder, International Cooperation, Genome-wide association study, Disease, 0302 clinical medicine, Risk Factors, Epidemiology, Odds Ratio, Medicine, genetics [Schizophrenia], Oligonucleotide Array Sequence Analysis, Genetics, Aged, 80 and over, bipolar disorder, 0303 health sciences, Middle Aged, 16p11.2, 3. Good health, Europe, Psychiatry and Mental health, genetics [Chromosomes, Human, Pair 16], epidemiology [Bipolar Disorder], Urological cancers Radboud Institute for Health Sciences [Radboudumc 15], genetics [Polymorphism, Single Nucleotide], Female, Adult, medicine.medical_specialty, Psychosis, Genotype, complications [Bipolar Disorder], epidemiology [Schizophrenia], Polymorphism, Single Nucleotide, Article, 03 medical and health sciences, Cellular and Molecular Neuroscience, Young Adult, complications [Schizophrenia], Internal medicine, mental disorders, Humans, Genetic Predisposition to Disease, ddc:610, Molecular Biology, Settore MED/25 - Psichiatria, 030304 developmental biology, Aged, Chromosome Aberrations, Neurodevelopmental disorders Donders Center for Medical Neuroscience [Radboudumc 7], business.industry, Gene Expression Profiling, Odds ratio, medicine.disease, Schizophrenia, Autism, business, Body mass index, genetics [Bipolar Disorder], 030217 neurology & neurosurgery, Chromosomes, Human, Pair 16, Genome-Wide Association Study
Abstract

To access publisher's full text version of this article. Please click on the hyperlink in Additional Links field. Epidemiological and genetic data support the notion that schizophrenia and bipolar disorder share genetic risk factors. In our previous genome-wide association study, meta-analysis and follow-up (totaling as many as 18 206 cases and 42 536 controls), we identified four loci showing genome-wide significant association with schizophrenia. Here we consider a mixed schizophrenia and bipolar disorder (psychosis) phenotype (addition of 7469 bipolar disorder cases, 1535 schizophrenia cases, 333 other psychosis cases, 808 unaffected family members and 46 160 controls). Combined analysis reveals a novel variant at 16p11.2 showing genome-wide significant association (rs4583255[T]; odds ratio=1.08; P=6.6 × 10(-11)). The new variant is located within a 593-kb region that substantially increases risk of psychosis when duplicated. In line with the association of the duplication with reduced body mass index (BMI), rs4583255[T] is also associated with lower BMI (P=0.0039 in the public GIANT consortium data set; P=0.00047 in 22 651 additional Icelanders). National Institute of Mental Health N01 MH900001 MH074027 1U24MH081810 R01 MH078075 Eli Lilly and Company Pritzker Neuropsychiatric Disorders Research Fund L.L.C. Massachusetts General Hospital in Boston, MA (NIMH) 2N01MH080001-001 Wellcome Trust 076113 085475 075491/Z/04 085475/B/08/Z 085475/Z/08/Z Medical Research Council G0601030 Anthony P Monaco, PI, University of Oxford National Genome Research Network of the German Federal Ministry of Education and Research (BMBF) 01GS08144 01GS08147 Centre of Excellence for Complex Disease Genetics of the Academy of Finland 213506 129680 Biocentrum Helsinki Foundation Research Program for Molecular Medicine, Faculty of Medicine, University of Helsinki Stanley Medical Research Institute Danish Council for Strategic Research 2101-07-0059 H Lundbeck A/S; the Research Council of Norway 163070/V50 Danish Medical Research Council South-East Norway Health Authority 2004-123 Medical Research Council Ministerio de Sanidad y Consumo, Spain PI081522 Xunta de Galicia 08CSA005208PR Swedish Research Council Wellcome Trust Case Control Consortium 2 Max Planck Society; Saarland University T6 03 10 00-45 Netherlands Foundation for Brain Research (Hersenstichting) 2008(1).34 2006-037761 PIAP-GA-2008-218251 HEALTH-F2-2009-223423 HEALTH-F4-2009-242257 info:eu-repo/grantAgreement/EC/FP7/218251

Published
2014

20. Identifying gene-environment interactions in schizophrenia: Contemporary challenges for integrated, large-scale investigations

Author

Van Os, J. Rutten, B.P. Myin-Germeys, I. Delespaul, P. Viechtbauer, W. Van Zelst, C. Bruggeman, R. Reininghaus, U. Morgan, C. Murray, R.M. Di Forti, M. McGuire, P. Valmaggia, L.R. Kempton, M.J. Gayer-Anderson, C. Hubbard, K. Beards, S. Stilo, S.A. Onyejiaka, A. Bourque, F. Modinos, G. Tognin, S. Calem, M. O'Donovan, M.C. Owen, M.J. Holmans, P. Williams, N. Craddock, N. Richards, A. Humphreys, I. Meyer-Lindenberg, A. Leweke, F.M. Tost, H. Akdeniz, C. Rohleder, C. Bumb, J.M. Schwarz, E. Alptekin, K. Üçok, A. Saka, M.C. Atbagoǧlu, E.C. Gülöksüz, S. Gumus-Akay, G. Cihan, B. Karadaǧ, H. Soygür, H. Cankurtaran, E.S. Ulusoy, S. Akdede, B. Binbay, T. Ayer, A. Noyan, H. Karadayi, G. Akturan, E. Ulaş, H. Arango, C. Parellada, M. Bernardo, M. Sanjuán, J. Bobes, J. Arrojo, M. Santos, J.L. Cuadrado, P. Solano, J.J.R. Carracedo, A. Bernardo, E.G. Roldán, L. López, G. Cabrera, B. Cruz, S. Mesa, E.M.D. Pouso, M. Jiménez, E. Sánchez, T. Rapado, M. González, E. Martínez, C. Sánchez, E. Olmeda, M.S. De Haan, L. Velthorst, E. Van Der Gaag, M. Selten, J.-P. Van Dam, D. Van Der Ven, E. Van Der Meer, F. Messchaert, E. Kraan, T. Burger, N. Leboyer, M. Szoke, A. Schürhoff, F. Llorca, P.-M. Jamain, S. Tortelli, A. Frijda, F. Vilain, J. Galliot, A.-M. Baudin, G. Ferchiou, A. Richard, J.-R. Bulzacka, E. Charpeaud, T. Tronche, A.-M. De Hert, M. Van Winkel, R. Decoster, J. Derom, C. Thiery, E. Stefanis, N.C. Sachs, G. Aschauer, H. Lasser, I. Winklbaur, B. Schlögelhofer, M. Riecher-Rössler, A. Borgwardt, S. Walter, A. Harrisberger, F. Smieskova, R. Rapp, C. Ittig, S. Soguel-Dit-Piquard, F. Studerus, E. Klosterkötter, J. Ruhrmann, S. Paruch, J. Julkowski, D. Hilboll, D. Sham, P.C. Cherny, S.S. Chen, E.Y.H. Campbell, D.D. Li, M. Romeo-Casabona, C.M. Cirión, A.E. Mora, A.U. Jones, P. Kirkbride, J. Cannon, M. Rujescu, D. Tarricone, I. Berardi, D. Bonora, E. Seri, M. Marcacci, T. Chiri, L. Chierzi, F. Storbini, V. Braca, M. Minenna, M.G. Donegani, I. Fioritti, A. La Barbera, D. La Cascia, C.E. Mulè, A. Sideli, L. Sartorio, R. Ferraro, L. Tripoli, G. Seminerio, F. Marinaro, A.M. McGorry, P. Nelson, B. Amminger, G.P. Pantelis, C. Menezes, P.R. Del-Ben, C.M. Tenan, S.H.G. Shuhama, R. Ruggeri, M. Tosato, S. Lasalvia, A. Bonetto, C. Ira, E. Nordentoft, M. Krebs, M.-O. Barrantes-Vidal, N. Cristóbal, P. Kwapil, T.R. Brietzke, E. Bressan, R.A. Gadelha, A. Maric, N.P. Andric, S. Mihaljevic, M. Mirjanic, T.

Abstract

Recent years have seen considerable progress in epidemiological and molecular genetic research into environmental and genetic factors in schizophrenia, but methodological uncertainties remain with regard to validating environmental exposures, and the population risk conferred by individual molecular genetic variants is small. There are now also a limited number of studies that have investigated molecular genetic candidate gene-environment interactions (G × E), however, so far, thorough replication of findings is rare and G × E research still faces several conceptual and methodological challenges. In this article, we aim to review these recent developments and illustrate how integrated, large-scale investigations may overcome contemporary challenges in G × E research, drawing on the example of a large, international, multi-center study into the identification and translational application of G × E in schizophrenia. While such investigations are now well underway, new challenges emerge for G × E research from late-breaking evidence that genetic variation and environmental exposures are, to a significant degree, shared across a range of psychiatric disorders, with potential overlap in phenotype. © 2014 The Author.

Published
2014

21. ¿Tienen una personalidad distinta los adolescentes consumidores de psicoestimulantes?

Author

Becoña, E., López, A., Fernández del Río, E., Martínez, U., Fraga, J., Osorio, J., Arrojo, M., López, F., Domínguez, and M. N.

Abstract

El consumo de psicoestimulantes tiene una especial importancia en nuestro medio por su notable incremento entre los más jóvenes. El objetivo del presente estudio es determinar si hay diferencias entre menores de edad consumidores y no consumidores de psicoestimulantes (cocaína y éxtasis) en función de las características de personalidad evaluadas con el MACI. La muestra está formada por 398 jóvenes entre 14 y 17 años que fueron seleccionados con un muestreo aleatorio en los domicilios de los entrevistados y en lugares de ocio y diversión. Los resultados confirman la existencia de importantes diferencias en las características de personalidad de ambos. Los jóvenes que han consumido psicoestimulantes se caracterizan por tener los prototipos de personalidad Rebelde, Rudo, Oposicionista y Tendencia límite. Do adolescents who use stimulants have a different personality? Stimulant consumption is especially important in our context because its use has greatly increased in recent years. The aim of the present study is to analyze the differences between stimulant users and nonusers (under 18 years old) in personality characteristics assessed with the MACI. The sample comprises 398 youths between 14 and 17 years old who were selected through random sampling in their homes or in recreational night spots. Results show important differences in personality features between stimulant users and nonusers. Stimulant users are characterized by having unruly, forceful, oppositional and borderline-tendency personality prototypes.

Published
2011

22. Common variants at VRK2 and TCF4 conferring risk of schizophrenia

Author

Steinberg, S., Jong, S. d., Genomics, I. S., Andreassen, O. A., Werge, T., Børglum, A. D., Mors, O., Mortensen, P. B., Gustafsson, O., Costas, J., O. P. H., Demontis, D., Papiol, S., Huttenlocher, J., Mattheisen, M., Breuer, R., Vassos, E., Giegling, I., Fraser, G., Walker, N., Tuulio Henriksson, A., Suvisaari, J., Lönnqvist, J., Paunio, T., Agartz, I., Melle, I., Djurovic, S., Strengman, E., G. R. O., Jürgens, G., Glenthøj, B., Terenius, L., Hougaard, D. M., Orntoft, T., Wiuf, C., Didriksen, M., Hollegaard, M. V., Nordentoft, M., Winkel, R. v., Kenis, G., Abramova, L., Kaleda, V., Arrojo, M., Sanjuán, J., Arango, C., Sperling, S., Rossner, M., Ribolsi, M., Magni, V., Siracusano, A., Christiansen, C., Kiemeney, L. A., Veldink, J., Den, L. v., Ingason, A., Muglia, P., Murray, R., Nöthen, M. M., Sigurdsson, E., Petursson, H., Thorsteinsdottir, U., Kong, A., Rubino, I. A., Hert, M. D., Réthelyi, J. M., Bitter, I., Jönsson, E. G., Golimbet, V., Carracedo, A., Ehrenreich, H., Craddock, N., Owen, M. J., O'Donovan, M. C., Case, W. T., Ruggeri, Mirella, Tosato, Sarah, Peltonen, L., Ophoff, R. A., Collier, D. A., Clair, D. S., Rietschel, M., Cichon, S., Stefansson, H., Rujescu, D., Stefansson, K., Psychiatrie & Neuropsychologie, RS: MHeNs School for Mental Health and Neuroscience, Amsterdam Neuroscience, Adult Psychiatry, and deCODE Genetics, IS-101 Reykjavik, Iceland.

Subjects
schizophrenia, sequence variants, TCF4, Genome-wide association study, Transcription Factor 4, 0302 clinical medicine, VRK2 protein, human, Polymorphism (computer science), Genotype, genetics [Schizophrenia], Neurogranin, Genetics (clinical), Schizophrenia, Risk, Alleles, Polymorphism, Single Nucleotide, Transcription Factors, Humans, Basic Helix-Loop-Helix Leucine Zipper Transcription Factors, Genetic Predisposition to Disease, Protein-Serine-Threonine Kinases, Genome-Wide Association Study, Genetics, 0303 health sciences, Association Studies Articles, Single Nucleotide, General Medicine, genetics [Transcription Factors], 3. Good health, Protein Serine-Threonine Kinases, Biology, genetics [Protein-Serine-Threonine Kinases], Molecular epidemiology [NCEBP 1], 03 medical and health sciences, ddc:570, Polymorphism, Allele, genetics [Basic Helix-Loop-Helix Leucine Zipper Transcription Factors], Settore MED/25 - Psichiatria, Molecular Biology, Molecular epidemiology Aetiology, screening and detection [NCEBP 1], 030304 developmental biology, Intron, Odds ratio, Molecular biology, TCF4 protein, human, 030217 neurology & neurosurgery
Abstract

To access publisher full text version of this article. Please click on the hyperlink in Additional Links field. Common sequence variants have recently joined rare structural polymorphisms as genetic factors with strong evidence for association with schizophrenia. Here we extend our previous genome-wide association study and meta-analysis (totalling 7 946 cases and 19 036 controls) by examining an expanded set of variants using an enlarged follow-up sample (up to 10 260 cases and 23 500 controls). In addition to previously reported alleles in the major histocompatibility complex region, near neurogranin (NRGN) and in an intron of transcription factor 4 (TCF4), we find two novel variants showing genome-wide significant association: rs2312147[C], upstream of vaccinia-related kinase 2 (VRK2) [odds ratio (OR) = 1.09, P = 1.9 × 10(-9)] and rs4309482[A], between coiled-coiled domain containing 68 (CCDC68) and TCF4, about 400 kb from the previously described risk allele, but not accounted for by its association (OR = 1.09, P = 7.8 × 10(-9)). European Union LSHM-CT-2006-037761 PIAP-GA-2008-218251 HEALTH-F2-2009-223423 National Genome Research Network of the German Federal Ministry of Education and Research (BMBF) 01GS08144 01GS08147 National Institute of Mental Health R01 MH078075 N01 MH900001 MH074027 Centre of Excellence for Complex Disease Genetics of the Academy of Finland 213506 129680 Biocentrum Helsinki Foundation Faculty of Medicine, University of Helsinki Stanley Medical Research Institute Danish Council for Strategic Research 2101-07-0059 H. Lundbeck A/S Research Council of Norway 163070/V50 South-East Norway Health Authority 2004-123 Medical Research Council Ministerio de Sanidad y Consumo, Spain PI081522 Xunta de Galicia 08CSA005208PR Swedish Research Council Wellcome Trust 083948/Z/07/Z Max Planck Society Eli Lilly and Company info:eu-repo/grantAgreement/EC/FP7/218251

Published
2011

23. [Response to electroconvulsive therapy in a case of erotomania]

Author

Arrojo M, Esteves M, Ferreira P, and ANTONIO PALHA

Subjects
Adult, Schizophrenia, Paranoid, Treatment Outcome, Erotica, Humans, Female, Electroconvulsive Therapy
Abstract

Secondary erotomania has mainly been associated with functional psychosis (especially schizophrenia) and bipolar disorder. Traditionally, erotomania has been considered chronic and refractory to treatment, although cases of secondary erotomania with response to benzodiazepines, lithium, anticonvulsivants, antipsychotic drugs and electroconvulsive therapy have been described. In this paper, we present a clinical case of secondary erotomania related to paranoid schizophrenia with good response to electroconvulsive therapy and neuroleptics. Actas Esp Psiquiatr 2003;31(6):361-363

Published
2003

24. [Interface neurology/psychiatry: a case report of neurosyphilis]

Author

Silva A, Arrojo M, Ferreira P, Mj, Sa, and ANTONIO PALHA

Subjects
Adult, Diagnosis, Differential, Male, Psychotic Disorders, Neurosyphilis, Brain, Humans
Abstract

Organic diseases can occur with different psychiatric symptoms. Neurosyphilis was considered to be a landmark in the history of organic mental syndromes. The complexity of its clinical picture decreases the boundaries between Neurology and Psychiatry and requires a multidisciplinary approach. We report a case of neurosyphilis that began with psychiatric symptoms in a twenty five years old male.

Published
2003

25. La regla contra las perpetuidades en el derecho inglés

Author

Fernández-Arrojo, M. (María) and Arechederra-Aranzadi, L.I. (Luis Ignacio)

Subjects
derecho inglés, Derecho [Materias Investigacion], common law, derecho de la propiedad
Abstract

La regla contra las perpetuidades es un limite a la facultad de disponer del propietario que establece un equilibrio entre los intereses jurídicos relativos a la disposición de miembros de generaciones sucesivas. La tesis tiene tres capítulos: El primero analiza diversos conceptos del derecho ingles necesarios para entender la descripción posterior de la institución estudiada. Todos ellos pertenecen al área jurídica de la propiedad. El segundo capitulo contiene el análisis global del principio contra la perpetuidad; El estudio comienza con los derechos contingentes, objeto del mismo. Después se analiza el medio con que cuenta el derecho ingles para crear derechos limitados y sucesivos en los bienes, o instrumento de la vinculación. En tercer lugar se realiza un estudio histórico desde dos perspectivas: La jurídica y la socio-económica. Finalmente, se describe la operatividad del principio, tal y como vige actualmente. El tercer capitulo describe las dos vertientes de la polémica a que ha dado lugar esta regla en las ultimas décadas. Por un lado, una discusión sobre la función actual del principio y, por otro, los diversos conceptos defendidos de las "vidas medidoras del periodo de perpetuidad" en la doctrina, así como un estudio de dicho concepto a través de la jurisprudencia del Common Law.

Published
1996

28. Genetic and psychosocial stressors have independent effects on the level of subclinical psychosis: findings from the multinational EU-GEI study

Author

B. Pignon, H. Peyre, A. Ayrolles, J. B. Kirkbride, S. Jamain, A. Ferchiou, J. R. Richard, G. Baudin, S. Tosato, H. Jongsma, L. de Haan, I. Tarricone, M. Bernardo, E. Velthorst, M. Braca, C. Arango, M. Arrojo, J. Bobes, C. M. Del-Ben, M. Di Forti, C. Gayer-Anderson, P. B. Jones, C. La Cascia, A. Lasalvia, P. R. Menezes, D. Quattrone, J. Sanjuán, J. P. Selten, A. Tortelli, P. M. Llorca, J. van Os, B. P. F. Rutten, R. M. Murray, C. Morgan, M. Leboyer, A. Szöke, F. Schürhoff, Pignon B., Peyre H., Ayrolles A., Kirkbride J.B., Jamain S., Ferchiou A., Richard J.R., Baudin G., Tosato S., Jongsma H., de Haan L., Tarricone I., Bernardo M., Velthorst E., Braca M., Arango C., Arrojo M., Bobes J., Del-Ben C.M., Di Forti M., Gayer-Anderson C., Jones P.B., La Cascia C., Lasalvia A., Menezes P.R., Quattrone D., Sanjuan J., Selten J.P., Tortelli A., Llorca P.M., van Os J., Rutten B.P.F., Murray R.M., Morgan C., Leboyer M., Szoke A., Schurhoff F., Pignon, B [0000-0003-0526-3136], Ayrolles, A [0000-0002-3202-0781], Kirkbride, JB [0000-0003-3401-0824], Tosato, S [0000-0002-9665-7538], Lasalvia, A [0000-0001-9963-6081], Morgan, C [0000-0002-1386-2369], Apollo - University of Cambridge Repository, Pignon, B, Peyre, H, Ayrolles, A, Kirkbride, J B, Jamain, S, Ferchiou, A, Richard, J R, Baudin, G, Tosato, S, Jongsma, H, de Haan, L, Tarricone, I, Bernardo, M, Velthorst, E, Braca, M, Arango, C, Arrojo, M, Bobes, J, Del-Ben, C M, Di Forti, M, Gayer-Anderson, C, Jones, P B, La Cascia, C, Lasalvia, A, Menezes, P R, Quattrone, D, Sanjuán, J, Selten, J P, Tortelli, A, Llorca, P M, van Os, J, Rutten, B P F, Murray, R M, Morgan, C, Leboyer, M, Szöke, A, Schürhoff, F, Adult Psychiatry, APH - Mental Health, ANS - Complex Trait Genetics, ANS - Mood, Anxiety, Psychosis, Stress & Sleep, Psychiatrie & Neuropsychologie, RS: MHeNs - R2 - Mental Health, MUMC+: Hersen en Zenuw Centrum (3), MUMC+: VPK Flexteam IC (9), MUMC+: MA Psychiatrie (3), and RS: MHeNs - R3 - Neuroscience

Subjects
Schizophrenia/genetics, Environmental effects on human beings, Risk factors in diseases, Epidemiology, Psicosi, psychosi, Pathological psychology, Genes × environment interaction, Risk Factors, Settore MED/48 -Scienze Infermierist. e Tecn. Neuro-Psichiatriche e Riabilitat, psychosocial stressors, Humans, psychosis, Psychotic Disorders/genetics, Settore MED/25 - Psichiatria, Influència del medi ambient en l'home, Genètica de la conducta, Factors de risc en les malalties, Genes × environment interactions, Public Health, Environmental and Occupational Health, Psychoses, polygenic risk score for schizophrenia, Psicopatologia, Psychiatry and Mental health, Psychotic Disorders, Behavior genetics, Schizophrenia, Esquizofrènia, Gene-Environment Interaction
Abstract

the Spanish Ministry of Science and Innovation. Instituto de Salud Carlos III (SAM16PE07CP1, PI16/02012, PI19/024), co-financed by ERDF Funds from the European Commission, ‘A way of making Europe’, CIBERSAM. Madrid Regional Government (B2017/BMD-3740 AGES-CM-2), European Union Structural Funds. European Union Seventh Framework Program under grant agreements FP7-4-HEALTH-2009-2.2.1-2-241909 (Project EU-GEI) and FP7-HEALTH-2013-2.2.1-2-603196 (Project PSYSCAN); and European Union H2020 Program under the Innovative Medicines Initiative 2 Joint Undertaking (grant agreement No 115916, Project PRISM, and grant agreement No 777394, Project AIMS-2-TRIALS) (...), Pignon B, Peyre H, Ayrolles A, Kirkbride JB, Jamain S, Ferchiou A, Richard JR, Baudin G, Tosato S, Jongsma H, de Haan L, Tarricone I, Bernardo M, Velthorst E, Braca M, Arango C, Arrojo M, Bobes J, Del-Ben CM, Di Forti M, Gayer-Anderson C, Jones PB, La Cascia C, Lasalvia A, Menezes PR, Quattrone D, Sanjuán J, Selten JP, Tortelli A, Llorca PM, van Os J, Rutten BPF, Murray RM, Morgan C, Leboyer M, Szöke A, Schürhoff F

Published
2022
Full Text
View/download PDF

29. The Independent Effects of Psychosocial Stressors on Subclinical Psychosis: Findings from the Multinational EU-GEI Study

Author

Andrea Tortelli, Peter B. Jones, Jim van Os, Caterina La Cascia, Bart P. F. Rutten, Eva Velthorst, Baptiste Pignon, Celso Arango, Sarah Tosato, Lieuwe de Haan, Julio Sanjuán, Marion Leboyer, James B. Kirkbride, Antonio Lasalvia, Diego Quattrone, Cristina Marta Del-Ben, Andrei Szöke, Grégoire Baudin, Charlotte Gayer-Anderson, Pierre-Michel Llorca, Paulo Rossi Menezes, Robin M. Murray, Julio Bobes, Hannah E Jongsma, Miguel Bernardo, Mohamed Lajnef, Jean-Paul Selten, Hugo Peyre, Jean-Romain Richard, Franck Schürhoff, Craig Morgan, Marta Di Forti, Ilaria Tarricone, Mauro Braca, Manuel Arrojo, Aziz Ferchiou, Pignon, B., Lajnef, M., Kirkbride, J.B., Peyre, H., Ferchiou, A., Richard, J.-R., Baudin, G., Tosato, S., Jongsma, H., De Haan, L., Tarricone, I., Bernardo, M., Velthorst, E., Braca, M., Arango, C., Arrojo, M., Bobes, J., Del-Ben, C.M., Di Forti, M., Gayer-Anderson, C., Jones, P.B., La Cascia, C., Lasalvia, A., Menezes, P.R., Quattrone, D., Sanjuán, J., Selten, J.-P., Tortelli, A., Llorca, P.-M., Van Os, J., Rutten, B.P.F., Murray, R.M., Morgan, C., Leboyer, M., Szöke, A., Schürhoff, F., Pôle de Psychiatrie [Hôpital Henri Mondor], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital H. Mondor - A. Chenevier, Adult Psychiatry, APH - Mental Health, ANS - Complex Trait Genetics, ANS - Mood, Anxiety, Psychosis, Stress & Sleep, Pignon B., Lajnef M., Kirkbride J.B., Peyre H., Ferchiou A., Richard J.-R., Baudin G., Tosato S., Jongsma H., De Haan L., Tarricone I., Bernardo M., Velthorst E., Braca M., Arango C., Arrojo M., Bobes J., Del-Ben C.M., Di Forti M., Gayer-Anderson C., Jones P.B., La Cascia C., Lasalvia A., Menezes P.R., Quattrone D., Sanjuan J., Selten J.-P., Tortelli A., Llorca P.-M., Van Os J., Rutten B.P.F., Murray R.M., Morgan C., Leboyer M., Szoke A., Schurhoff F., Psychiatrie & Neuropsychologie, RS: MHeNs - R2 - Mental Health, MUMC+: MA Psychiatrie (3), MUMC+: Hersen en Zenuw Centrum (3), and RS: MHeNs - R3 - Neuroscience

Subjects
Male, stressful life events, Schizotypy, positive subclinical symptom, Ethnic group, Social Environment, subclinical psychosis, positive subclinical symptoms, 0302 clinical medicine, Adverse Childhood Experiences, Settore MED/48 -Scienze Infermierist. e Tecn. Neuro-Psichiatriche e Riabilitat, SINTOMAS PSÍQUICOS, subclinical psychosi, 10. No inequality, COMMUNITY ASSESSMENT, Subclinical infection, GENERAL-POPULATION, psychotic symptom, Depression, Confounding, Social Discrimination, depressive subclinical symptom, stressful life event, ETHNIC-GROUPS, 3. Good health, Psychiatry and Mental health, NEIGHBORHOOD CHARACTERISTICS, ADULT PSYCHIATRIC-DISORDERS, psychotic symptoms, Adverse Childhood Experience, Female, psychosocial stress, Psychology, Psychosocial, Human, Clinical psychology, negative subclinical symptom, psychosocial stre, Adult, Psychosis, Sibling, LIFE EVENTS, schizotypy, Psychotic Disorder, 03 medical and health sciences, Community Assessment of Psychic Experiences (CAPE), THREATENING EXPERIENCES, medicine, Humans, European Union, Settore MED/25 - Psichiatria, childhood trauma, Siblings, Stressor, medicine.disease, PERCEIVED DISCRIMINATION, negative subclinical symptoms, 030227 psychiatry, PSYCHOMETRIC PROPERTIES, Psychotic Disorders, [SDV.MHEP.PSM]Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental health, dis crimination, social capital, depressive subclinical symptoms, Stress, Psychological, 030217 neurology & neurosurgery, Regular Articles, discrimination
Abstract

The influence of psychosocial stressors on psychosis risk has usually been studied in isolation and after the onset of the disorder, potentially ignoring important confounding relationships or the fact that some stressors that may be the consequence of the disorder rather than preexisting. The study of subclinical psychosis could help to address some of these issues. In this study, we investigated whether there was (i) an association between dimensions of subclinical psychosis and several psychosocial stressors including: childhood trauma, self-reported discrimination experiences, low social capital, and stressful life experiences, and (ii) any evidence of environment-environment (ExE) interactions between these factors. Data were drawn from the EUGEI study, in which healthy controls (N = 1497) and siblings of subjects with a psychotic disorder (N = 265) were included in six countries. The association between psychosocial stressors and subclinical psychosis dimensions (positive, negative and depressive dimension as measured by the Community Assessment of Psychic Experiences (CAPE) scale) and possible ExE interactions were assessed using linear regression models. After adjusting for sex, age, ethnicity, country, and control/sibling status, childhood trauma (beta for positive dimension: 0.13, negative: 0.49, depressive: 0.26) and stressful life events (positive: 0.08, negative: 0.16, depressive: 0.17) were associated with the three dimensions. Lower social capital was associated with the negative and depression dimensions (negative: 0.26, depressive: 0.13), and self-reported discrimination experiences with the positive dimension (0.06). Our findings are in favor of independent, cumulative and non-specific influences of social adversities in subclinical psychosis in non-clinical populations, without arguments for E * E interactions. © The Author(s) 2021. Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Published
2021

30. Identifying gene-environment interactions in schizophrenia: contemporary challenges for integrated, large-scale investigations

Author

Rosana Shuhama, Gonzalo López, Viviana Storbini, Tolga Binbay, Ma Soledad Olmeda, Maria Calem, Marina Mihaljevic, Christos Pantelis, Halis Ulaş, Eva Velthorst, Jeroen Decoster, J. Malte Bumb, Ruud van Winkel, E. Cem Atbasoglu, Wolfgang Viechtbauer, Mirella Ruggeri, Erich Studerus, Daniele La Barbera, Domenico Berardi, Anita Riecher-Rössler, Stefan Borgwardt, Elsje van der Ven, Charlotte Rapp, Desiree Hilboll, Mark van der Gaag, Chiara Bonetto, Marie-Odile Krebs, Silvia Tenan, Monika Schlögelhofer, Robin M. Murray, Caterina La Cascia, Philip McGuire, Simona A. Stilo, Desmond Campbell, Fabienne Harrisberger, Teresa Sánchez, Catherine Derom, Franck Schürhoff, Philippe Delespaul, Jose Luis Santos, Emilio Sánchez, Stephan Ruhrmann, Luigi Rocco Chiri, Sabrina Cruz, Handan Noyan, Dominika Julkowski, Celso Arango, Merete Nordentoft, Stacey S. Cherny, Anne-Marie Galliot, Daniella van Dam, María Pouso, Asier Urruela Mora, G. Paul Amminger, Enrique García Bernardo, Ahmet Ayer, Tijana Mirjanic, Andrei Szöke, Anna Walter, Antonio Lasalvia, Isla Humphreys, Flora Frijda, Lieuwe de Haan, Neus Barrantes-Vidal, Nigel Williams, Burçin Cihan, Matthew J. Kempton, Ceren Akdeniz, Tamar Kraan, Andrea Tortelli, Barnaby Nelson, Marta Di Forti, Angelo Fioritti, Pedro Cuadrado, Eylem Sahin Cankurtaran, Emanuel Schwarz, Andreas Meyer-Lindenberg, Ilaria Tarricone, Laura Ferraro, Dan Rujescu, Anne-Marie Tronche, Laura Roldan, Bibiana Cabrera, Alp Üçok, Craig Morgan, Julio Sanjuán, Mauro Braca, Julio Bobes, Eric Y.H. Chen, Michael Conlon O'Donovan, Peter Holmans, Harald N. Aschauer, Sarah Ittig, Covadonga Martínez, Iris Lasser, Emiliano González, Aitziber Emaldi Cirión, Rachele Sartorio, F. Seminerio, Rodrigo A. Bressan, Ulrich Reininghaus, Elisa Brietzke, François Bourque, G Tripoli, Inez Myin-Germeys, Aziz Ferchiou, Gemma Modinos, Grégoire Baudin, Fabienne Soguel-Dit-Piquard, Cristina Marta Del-Ben, Gabriele Sachs, Elçin Akturan, Manuel Arrojo, Thomas R. Kwapil, Alice Mulè, Eva Mª Díaz Mesa, Federico Chierzi, Köksal Alptekin, Floor J. van der Meer, Pak C. Sham, Jim van Os, Adanna Onyejiaka, Mara Parellada, Bart P. F. Rutten, Jeanne Vilain, Michael John Owen, Sarah Tosato, Haldan Soygür, A.M. Marinaro, Stefania Tognin, Evert Thiery, Cathrin Rohleder, Mary Cannon, Miaoxin Li, F. Markus Leweke, Marc De Hert, Marta Rapado, Maria Gabriella Minenna, Pierre-Michel Llorca, Alexander Richards, Stéphane Jamain, Elles Messchaert, Nadja P. Maric, Semra Ulusoy, Elisa Ira, Peter G. Jones, Paulo Rossi Menezes, Patrick D. McGorry, Bernadette Winklbaur, Stephanie Beards, Nadine Burger, Güvem Gümüş-Akay, Marion Leboyer, James B. Kirkbride, Sinan Guloksuz, Ary Gadelha, E. Bulzacka, Carlos M. Romeo-Casabona, Gülşah Karadayı, Jean-Paul Selten, José Juan Rodríguez Solano, Kathryn Hubbard, Estela Jiménez, Thomas Charpeaud, Nikos C. Stefanis, Lucia Sideli, Miguel Bernardo, Jean-Romain Richard, Ivonne Donegani, Marco Seri, Lucia Valmaggia, Julia Paruch, Catherine van Zelst, Meram Can Saka, Heike Tost, Renata Smieskova, Thomas Marcacci, Nicholas John Craddock, Berna Binnur Akdede, Joachim Klosterkötter, Richard Bruggeman, Charlotte Gayer-Anderson, Sanja Andric, Elena Bonora, Angel Carracedo, Hasan Karadağ, Paula Cristobal, ANS - Amsterdam Neuroscience, Adult Psychiatry, Graduate School, Perceptual and Cognitive Neuroscience (PCN), Maastricht Univ, Kings Coll London, Mondriaan Mental Hlth Trust, Univ Groningen, Cardiff Univ, Cent Inst Mental Hlth, Dokuz Eylul Univ, Istanbul Univ, Ankara Univ, Yale Univ, Middle E Tech Univ, Diskapi YB Res & Training Hosp, Turkish Federat Schizophrenia Assoc, Ataturk Training & Res Hosp, Manisa Mental Hlth Hosp, Univ Complutense, Univ Barcelona, Univ Valencia, Univ Oviedo, Univ Santiago de Compostela, Hosp Virgen de la Luz, Hosp Univ Infanta Leonor Hosp Virgen Torre, Hosp Clin Univ, Hosp Psiquiatr Conxo, Univ Amsterdam, Vrije Univ Amsterdam, EMGO Inst Hlth & Care Res, Parnassia Psychiat Inst, Rivierduinen Psychiat Inst, Grp Hosp Mondor, Hop Henri Mondor, Univ Paris Est, Fdn Fondamental, CMP B CHU, Univ Auvergne, EPS Maison Blanche, UPC KU Leuven, UPC, Katholieke Univ Leuven, Assoc Sci Res Multiple Births, Univ Ghent, Univ Athens, Med Univ Vienna, Psychiat Univ Clin Basel, Univ Cologne, Univ Hong Kong, Univ Basque Country, Univ Zaragoza, Univ Cambridge, UCL, Royal Coll Surgeons Ireland, Univ Munich, Univ Bologna, Local Hlth Trust, Univ Palermo, P Giaccone Gen Hosp, Univ Melbourne, Universidade de São Paulo (USP), Univ Verona, Copenhagen Univ Hosp, Univ Paris 05, Univ Autonoma Barcelona, St Pere Claver Fundacio Sanitaria, Univ N Carolina, CIBERSAM, Universidade Federal de São Paulo (UNIFESP), Univ Belgrade, van Os J, Rutten BP, Myin-Germeys I, Delespaul P, Viechtbauer W, van Zelst C, Bruggeman R, Reininghaus U, Morgan C, Murray RM, Di Forti M, McGuire P, Valmaggia LR, Kempton MJ, Gayer-Anderson C, Hubbard K, Beards S, Stilo SA, Onyejiaka A, Bourque F, Modinos G, Tognin S, Calem M, O'Donovan MC, Owen MJ, Holmans P, Williams N, Craddock N, Richards A, Humphreys I, Meyer-Lindenberg A, Leweke FM, Tost H, Akdeniz C, Rohleder C, Bumb JM, Schwarz E, Alptekin K, Üçok A, Saka MC, Atbaşoğlu EC, Gülöksüz S, Gumus-Akay G, Cihan B, Karadağ H, Soygür H, Cankurtaran EŞ, Ulusoy S, Akdede B, Binbay T, Ayer A, Noyan H, Karadayı G, Akturan E, Ulaş H, Arango C, Parellada M, Bernardo M, Sanjuán J, Bobes J, Arrojo M, Santos JL, Cuadrado P, Rodríguez Solano JJ, Carracedo A, García Bernardo E, Roldán L, López G, Cabrera B, Cruz S, Díaz Mesa EM, Pouso M, Jiménez E, Sánchez T, Rapado M, González E, Martínez C, Sánchez E, Olmeda MS, de Haan L, Velthorst E, van der Gaag M, Selten JP, van Dam D, van der Ven E, van der Meer F, Messchaert E, Kraan T, Burger N, Leboyer M, Szoke A, Schürhoff F, Llorca PM, Jamain S, Tortelli A, Frijda F, Vilain J, Galliot AM, Baudin G, Ferchiou A, Richard JR, Bulzacka E, Charpeaud T, Tronche AM, De Hert M, van Winkel R, Decoster J, Derom C, Thiery E, Stefanis NC, Sachs G, Aschauer H, Lasser I, Winklbaur B, Schlögelhofer M, Riecher-Rössler A, Borgwardt S, Walter A, Harrisberger F, Smieskova R, Rapp C, Ittig S, Soguel-dit-Piquard F, Studerus E, Klosterkötter J, Ruhrmann S, Paruch J, Julkowski D, Hilboll D, Sham PC, Cherny SS, Chen EY, Campbell DD, Li M, Romeo-Casabona CM, Emaldi Cirión A, Urruela Mora A, Jones P, Kirkbride J, Cannon M, Rujescu D, Tarricone I, Berardi D, Bonora E, Seri M, Marcacci T, Chiri L, Chierzi F, Storbini V, Braca M, Minenna MG, Donegani I, Fioritti A, La Barbera D, La Cascia CE, Mulè A, Sideli L, Sartorio R, Ferraro L, Tripoli G, Seminerio F, Marinaro AM, McGorry P, Nelson B, Amminger GP, Pantelis C, Menezes PR, Del-Ben CM, Gallo Tenan SH, Shuhama R, Ruggeri M, Tosato S, Lasalvia A, Bonetto C, Ira E, Nordentoft M, Krebs MO, Barrantes-Vidal N, Cristóbal P, Kwapil TR, Brietzke E, Bressan RA, Gadelha A, Maric NP, Andric S, Mihaljevic M, Mirjanic T, Clinical Psychology, EMGO+ - Mental Health, Van Os, J., Rutten, B., Myin Germeys, I., Delespaul, P., Viechtbauer, W., Van Zelst, C., Bruggeman, R., Reininghaus, U., Morgan, C., Murray, R., Di Forti, M., Mcguire, P., Valmaggia, L., Kempton, M., Gayer Anderson, C., Hubbard, K., Beards, S., Stilo, S., Onyejiaka, A., Bourque, F., Modinos, G., Tognin, S., Calem, M., O'Donovan, M., Owen, M., Holmans, P., Williams, N., Craddock, N., Richards, A., Humphreys, I., Meyer Lindenberg, A., Leweke, F., Tost, H., Akdeniz, C., Rohleder, C., Bumb, J., Schwarz, E., Alptekin, K., Üçok, A., Saka, M., Atbagoǧlu, E., Gülöksüz, S., Gumus Akay, G., Cihan, B., Karadaǧ, H., Soygür, H., Cankurtaran, E., Ulusoy, S., Akdede, B., Binbay, T., Ayer, A., Noyan, H., Karadayi, G., Akturan, E., Ulaş, H., Arango, C., Parellada, M., Bernardo, M., Sanjuán, J., Bobes, J., Arrojo, M., Santos, J., Cuadrado, P., Solano, J., Carracedo, A., Bernardo, E., Roldán, L., López, G., Cabrera, B., Cruz, S., Mesa, E., Pouso, M., Jiménez, E., Sánchez, T., Rapado, M., González, E., Martínez, C., Sánchez, E., Olmeda, M., De Haan, L., Velthorst, E., Van Der Gaag, M., Selten, J., Van Dam, D., Van Der Ven, E., Van Der Meer, F., Messchaert, E., Kraan, T., Burger, N., Leboyer, M., Szoke, A., Schürhoff, F., Llorca, P., Jamain, S., Tortelli, A., Frijda, F., Vilain, J., Galliot, A., Baudin, G., Ferchiou, A., Richard, J., Bulzacka, E., Charpeaud, T., Tronche, A., De Hert, M., Van Winkel, R., Decoster, J., Derom, C., Thiery, E., Stefanis, N., Sachs, G., Aschauer, H., Lasser, I., Winklbaur, B., Schlögelhofer, M., Riecher Rössler, A., Borgwardt, S., Walter, A., Harrisberger, F., Smieskova, R., Rapp, C., Ittig, S., Soguel Dit Piquard, F., Studerus, E., Klosterkötter, J., Ruhrmann, S., Paruch, J., Julkowski, D., Hilboll, D., Sham, P., Cherny, S., Chen, E., Campbell, D., Li, M., Romeo Casabona, C., Cirión, A., Mora, A., Jones, P., Kirkbride, J., Cannon, M., Rujescu, D., Tarricone, I., Berardi, D., Bonora, E., Seri, M., Marcacci, T., Chiri, L., Chierzi, F., Storbini, V., Braca, M., Minenna, M., Donegani, I., Fioritti, A., LA BARBERA, D., LA CASCIA, C., Mulè, A., Sideli, L., Sartorio, C., Ferraro, L., Tripoli, G., Seminerio, F., Marinaro, A., Mcgorry, P., Nelson, B., Amminger, G., Pantelis, C., Menezes, P., Del Ben, C., Tenan, S., Shuhama, R., Ruggeri, M., Tosato, S., Lasalvia, A., Bonetto, C., Ira, E., Nordentoft, M., Krebs, M., Barrantes Vidal, N., Cristóbal, P., Kwapil, T., Brietzke, E., Bressan, R., Gadelha, A., Maric, N., Andric, S., Mihaljevic, M., Mirjanic, T., Psychiatrie & Neuropsychologie, Promovendi MHN, and RS: MHeNs - R2 - Mental Health

Subjects
URBANICITY, Schizophrenia (object-oriented programming), CHILDHOOD, Genome-wide association study, VARIANTS, Social Environment, psychosi, 03 medical and health sciences, 0302 clinical medicine, PSYCHOSIS, epidemiology, gene-environment interaction, genetics, psychosis, schizophrenia, SDG 3 - Good Health and Well-being, RISK-FACTOR, Settore M-PSI/08 - Psicologia Clinica, Genetic variation, Humans, Genetic Predisposition to Disease, GENOME-WIDE ASSOCIATION, Gene, Settore MED/25 - Psichiatria, METAANALYSIS, Scale (chemistry), Psychosis, Genetic variants, Environment and Schizophrenia Invited, CANNABIS USE, 3. Good health, 030227 psychiatry, Psychiatry and Mental health, Evolutionary biology, Identification (biology), Schizophrenic Psychology, Population Risk, genetic, Psychology, FOLLOW-UP, 030217 neurology & neurosurgery, FUTURE-DIRECTIONS, Clinical psychology
Abstract

European Community Recent years have seen considerable progress in epidemiological and molecular genetic research into environmental and genetic factors in schizophrenia, but methodological uncertainties remain with regard to validating environmental exposures, and the population risk conferred by individual molecular genetic variants is small. There are now also a limited number of studies that have investigated molecular genetic candidate gene-environment interactions (G x E), however, so far, thorough replication of findings is rare and G x E research still faces several conceptual and methodological challenges. in this article, we aim to review these recent developments and illustrate how integrated, large-scale investigations may overcome contemporary challenges in G x E research, drawing on the example of a large, international, multi-center study into the identification and translational application of G x E in schizophrenia. While such investigations are now well underway, new challenges emerge for G x E research from late-breaking evidence that genetic variation and environmental exposures are, to a significant degree, shared across a range of psychiatric disorders, with potential overlap in phenotype. Maastricht Univ, Med Ctr, Dept Psychiat & Neuropsychol, Sch Mental Hlth & Neurosci,South Limburg Mental H, NL-6200 MD Maastricht, Netherlands Kings Coll London, Inst Psychiat, Dept Psychosis Studies, London WC2R 2LS, England Mondriaan Mental Hlth Trust, Maastricht, Heerlen, Netherlands Univ Groningen, Univ Med Ctr Groningen, Rob Giel Clin Res, Univ Ctr Psychiat, Groningen, Netherlands Kings Coll London, Inst Psychiat, Dept Hlth Serv & Populat Res, London WC2R 2LS, England Kings Coll London, Inst Psychiat, Dept Psychol, London WC2R 2LS, England Cardiff Univ, MRC, Ctr Neuropsychiat Genet, Cardiff CF10 3AX, S Glam, Wales Cent Inst Mental Hlth, Dept Psychiat & Psychotherapy, Mannheim, Germany Dokuz Eylul Univ, Sch Med, Dept Psychiat, Konak, Turkey Istanbul Univ, Istanbul Fac Med, Dept Psychiat, Psychot Disorders Res Unit, Istanbul, Turkey Ankara Univ, Sch Med, Dept Psychiat, Cebeci Hosp, TR-06100 Ankara, Turkey Ankara Univ, Brain Res Ctr, TR-06100 Ankara, Turkey Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA Middle E Tech Univ, Dept Psychol, TR-06531 Ankara, Turkey Diskapi YB Res & Training Hosp, Ankara, Turkey Turkish Federat Schizophrenia Assoc, Ankara, Turkey Ataturk Training & Res Hosp, Psychiat Clin, Ankara, Turkey Manisa Mental Hlth Hosp, Manisa, Turkey Istanbul Univ, Expt Med Res Inst, Dept Adv Neurol Sci, Istanbul Fac Med, Istanbul, Turkey Univ Complutense, IiSGM CIBERSAM, Dept Child & Adolescent Psychiat, Hosp Gen Univ Gregorio Maranon,Sch Med, E-28040 Madrid, Spain Univ Barcelona, Dept Psychiat, Hosp Clin, IDIBAPS,Ctr Invest Biomed Red Salud Mental CIBERS, Barcelona, Spain Univ Valencia, Sch Med, Dept Psychiat, Ctr Invest Biomed Red Salud Mental CIBERSAM, Valencia, Spain Univ Oviedo, Sch Med, Dept Med,Psychiat Area, Ctr Invest Biomed Red Salud Mental CIBERSAM, Oviedo, Spain Univ Santiago de Compostela, Dept Mental Hlth & Drug Addit Assistance, Hlth Serv Galicia,Psychiat Genet Grp IDIS, Hosp Clin,Ctr Invest Biomedica Red Salud Mental C, Santiago de Compostela 15706, Spain Hosp Virgen de la Luz, Serv Psiquiat, Dept Psychiat, Cuenca, Spain Hosp Univ Infanta Leonor Hosp Virgen Torre, Villa de Vallecas Mental Hlth Ctr, Villa de Vallecas Mental Hlth Dept, Madrid, Spain Hosp Univ Infanta Leonor Hosp Virgen Torre, Puente de Vallecas Mental Hlth Dept, Ctr Salud Mental Puente Vallecas, Madrid, Spain Hosp Clin Univ, Fdn Publ Galega Med Xenomica, Santiago de Compostela, Spain Univ Complutense, Sch Med, Hosp Gen Univ Gregorio Maranon, Dept Psychiat, E-28040 Madrid, Spain Hosp Psiquiatr Conxo, Santiago de Compostela, Spain Univ Amsterdam, Acad Med Ctr, Early Psychosis Sect, Dept Psychiat, NL-1105 AZ Amsterdam, Netherlands Vrije Univ Amsterdam, Dept Clin Psychol, Amsterdam, Netherlands EMGO Inst Hlth & Care Res, Amsterdam, Netherlands Parnassia Psychiat Inst, Dept Psychosis Res, the Hague, Netherlands Rivierduinen Psychiat Inst, Leiden, Netherlands Grp Hosp Mondor, AP HP, Creteil, France Hop Henri Mondor, INSERM, U955, Equipe 15, F-94010 Creteil, France Univ Paris Est, Fac Med, Creteil, France Fdn Fondamental, Creteil, France CMP B CHU, F-63003 Clermont Ferrand 1, France Univ Auvergne, EA 7280, Clermont Ferrand, France EPS Maison Blanche, Paris, France UPC KU Leuven, Dept Neurosci, UPC, Kortenberg, Belgium UPC, Dept Neurosci, Res Grp Psychiat, Leuven, Belgium Katholieke Univ Leuven, Univ Hosp Gasthuisberg, Dept Human Genet, Leuven, Belgium Assoc Sci Res Multiple Births, Ghent, Belgium Univ Ghent, Dept Neurol, Ghent Univ Hosp, B-9000 Ghent, Belgium Univ Athens, Sch Med, Eginit Hosp, Athens 11528, Greece Med Univ Vienna, Dept Psychiat & Psychotherapy, Vienna, Austria Psychiat Univ Clin Basel, Ctr Gender Res & Early Detect, Basel, Switzerland Psychiat Univ Clin Basel, Diagnost & Crisis Intervent Ctr, Basel, Switzerland Univ Cologne, Dept Psychiat & Psychotherapy, D-50931 Cologne, Germany Univ Hong Kong, Li Ka Shing Fac Med, Ctr Genom Sci, State Key Lab Brain & Cognit Sci, Hong Kong, Hong Kong, Peoples R China Univ Hong Kong, Li Ka Shing Fac Med, Dept Psychiat, Hong Kong, Hong Kong, Peoples R China Univ Hong Kong, Queen Mary Hosp, Li Ka Shing Fac Med, State Key Lab Brain & Cognit Sci, Hong Kong, Hong Kong, Peoples R China Univ Hong Kong, Queen Mary Hosp, Li Ka Shing Fac Med, Dept Psychiat, Hong Kong, Hong Kong, Peoples R China Univ Basque Country, Univ Deusto, Interuniv Chair Law & Human Genome Prov Govt Bisk, Bilbao, Bizkaia, Spain Univ Zaragoza, Zaragoza, Spain Univ Cambridge, Dept Psychiat, Cambridge, England UCL, Div Psychiat, London, England Royal Coll Surgeons Ireland, Beaumont Hosp, Educ & Res Ctr, Dept Psychiat, Dublin 9, Ireland Univ Munich, Dept Psychiat, Div Mol & Clin Neurobiol, Munich, Germany Univ Bologna, Alma Mater Studiorium, Psychiat Unit, Dept Med & Surg Sci, Bologna, Italy Univ Bologna, Alma Mater Studiorium, Genet Unit, Dept Med & Surg Sci, Bologna, Italy Local Hlth Trust, Dept Mental Hlth & Pathol Addict, Bologna, Italy Univ Palermo, Sect Psychiat, Dept Expt Biomed & Clin Neurosci, Palermo, Italy P Giaccone Gen Hosp, Unit Psychiat, Palermo, Italy Univ Melbourne, Ctr Youth Mental Hlth, Parkville, Vic 3052, Australia Univ Melbourne, Melbourne Neuropsychiat Ctr, Carlton, Vic, Australia Univ São Paulo, Fac Med, Dept Med Prevent, BR-01246903 São Paulo, Brazil Univ São Paulo, Nucleo Pesquina Saude Mental Populac, São Paulo, Brazil Univ São Paulo, Fac Med Ribeirao Preto, Dept Neurociencias & Ciencias Comportamento, BR-14049 Ribeirao Preto, Brazil Univ Verona, Sect Psychiat, Dept Publ Hlth & Community Med, I-37100 Verona, Italy Copenhagen Univ Hosp, Res Unit, Mental Hlth Ctr Copenhagen, Copenhagen, Denmark Univ Paris 05, Fac Med, Serv Hosp Univ, Hop St Anne, Paris, France Univ Autonoma Barcelona, Dept Psicol Clin & Salut, E-08193 Barcelona, Spain St Pere Claver Fundacio Sanitaria, Dept Salut Mental, Barcelona, Spain Univ N Carolina, Dept Psychol, Greensboro, NC 27412 USA CIBERSAM, Spanish Mental Hlth Res Network, Barcelona, Spain Universidade Federal de São Paulo, Dept Psychiat, PRISMA Early Intervent Program, São Paulo, Brazil Univ Belgrade, Sch Med, Beograd, Serbia Universidade Federal de São Paulo, Dept Psychiat, PRISMA Early Intervent Program, São Paulo, Brazil European Community: HEALTH-F2-2009-241909 Web of Science

Published
2014

31. Jumping to conclusions, general intelligence, and psychosis liability: Findings from the multi-centre EU-GEI case-control study

Author

Fabio Seminerio, Andrei Szöke, Antonio Lasalvia, Diego Quattrone, Domenico Berardi, Jean-Paul Selten, Ilaria Tarricone, Peter B. Jones, Graham K. Murray, Miguel Bernardo, José Luis Santos, Pierre-Michel Llorca, Alexander Richards, Caterina La Cascia, Celso Arango, Manuel Arrojo, Victoria Rodriguez, Lieuwe de Haan, Craig Morgan, Crocettarachele Sartorio, Michael Conlon O'Donovan, Andrea Tortelli, Laura Ferraro, Julio Sanjuán, Robin M. Murray, Hannah E. Jongsma, Marta Di Forti, Cristina Marta Del-Ben, Eva Velthorst, Jim van Os, Daniele La Barbera, Bart P. F. Rutten, Julio Bobes, Sarah Tosato, Pak C. Sham, James B. Kirkbride, Paulo Rossi Menezes, Charlotte Gayer-Anderson, Giada Tripoli, Institut Pascal (IP), Centre National de la Recherche Scientifique (CNRS)-Université Clermont Auvergne (UCA)-Institut national polytechnique Clermont Auvergne (INP Clermont Auvergne), Université Clermont Auvergne (UCA)-Université Clermont Auvergne (UCA), Tripoli G., Quattrone D., Ferraro L., Gayer-Anderson C., Rodriguez V., La Cascia C., La Barbera D., Sartorio C., Seminerio F., Tarricone I., Berardi D., Szoke A., Arango C., Tortelli A., Llorca P.-M., De Haan L., Velthorst E., Bobes J., Bernardo M., Sanjuan J., Santos J.L., Arrojo M., Del-Ben C.M., Menezes P.R., Selten J.-P., Jones P.B., Jongsma H.E., Kirkbride J.B., Lasalvia A., Tosato S., Richards A., O'donovan M., Rutten B.P.F., Os J.V., Morgan C., Sham P.C., Murray R.M., Murray G.K., Di Forti M., Adult Psychiatry, ANS - Complex Trait Genetics, ANS - Mood, Anxiety, Psychosis, Stress & Sleep, APH - Mental Health, Tripoli, Giada, Quattrone, Diego, Ferraro, Laura, Gayer-Anderson, Charlotte, Rodriguez, Victoria, La Cascia, Caterina, La Barbera, Daniele, Sartorio, Crocettarachele, Seminerio, Fabio, Tarricone, Ilaria, Berardi, Domenico, Szöke, Andrei, Arango, Celso, Tortelli, Andrea, Llorca, Pierre-Michel, de Haan, Lieuwe, Velthorst, Eva, Bobes, Julio, Bernardo, Miguel, Sanjuán, Julio, Santos, Jose Lui, Arrojo, Manuel, Del-Ben, Cristina Marta, Menezes, Paulo Rossi, Selten, Jean-Paul, Jones, Peter B, Jongsma, Hannah E, Kirkbride, James B, Lasalvia, Antonio, Tosato, Sarah, Richards, Alex, O'Donovan, Michael, Rutten, Bart Pf, Os, Jim van, Morgan, Craig, Sham, Pak C, Murray, Robin M, Murray, Graham K, Di Forti, Marta, Psychiatrie & Neuropsychologie, RS: MHeNs - R2 - Mental Health, MUMC+: MA Psychiatrie (3), and MUMC+: Hersen en Zenuw Centrum (3)

Subjects
Male, MISCOMPREHENSION, Intelligence, DELÍRIO, 0302 clinical medicine, Cognition, SCHIZOPHRENIA, psychotic-like experience, jumping to conclusions, Applied Psychology, Problem Solving, RISK, education.field_of_study, Middle Aged, 16. Peace & justice, Cognitive bias, 3. Good health, First episode psychosis, IQ, polygenic risk score, psychotic-like experiences, symptom dimensions, Psychiatry and Mental health, BIAS, Schizophrenia, RELIABILITY, Female, Original Article, jumping to conclusion, [SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC], medicine.symptom, Clinical psychology, Adult, Psychosis, Adolescent, DISORDERS, Population, REEXAMINATION, Delusions, 03 medical and health sciences, Young Adult, PEOPLE, medicine, Humans, Cognitive Dysfunction, education, DELUSIONAL IDEATION, Cognitive deficit, business.industry, Case-control study, medicine.disease, First episode psychosi, 030227 psychiatry, Psychotic Disorders, Case-Control Studies, Jumping to conclusions, business, 030217 neurology & neurosurgery
Abstract

This study was funded by the Medical Research Council, the European Community’s Seventh Framework Program grant [agreement HEALTH-F2-2009-241909 (Project EU-GEI)], São Paulo Research Foundation (grant 2012/0417-0), the National Institute for Health Research (NIHR) Biomedical Research Centre (BRC) at South London and Maudsley NHS Foundation Trust and King’s College London, the NIHR BRC at University College London and the Wellcome Trust (grant 101272/Z/12/Z)., Tripoli, G., Quattrone, D., Ferraro, L., Gayer-Anderson, C., Rodriguez, V., La Cascia, C., La Barbera, D., Sartorio, C., Seminerio, F., Tarricone, I., Berardi, D., Szöke, A., Arango, C., Tortelli, A., Llorca, P.-M., De Haan, L., Velthorst, E., Bobes, J., Bernardo, M., Sanjuán, J., Santos, J.L., Arrojo, M., Del-Ben, C.M., Menezes, P.R., Selten, J.-P., Jones, P.B., Jongsma, H.E., Kirkbride, J.B., Lasalvia, A., Tosato, S., Richards, A., O'donovan, M., Rutten, B.P.F., Os, J.V., Morgan, C., Sham, P.C., Murray, R.M., Murray, G.K., Di Forti, M.

Published
2021

32. The incidence of psychotic disorders among migrants and minority ethnic groups in Europe: findings from the multinational EU-GEI study

Author

Lieuwe de Haan, Jim van Os, Bart P. F. Rutten, Sarah Tosato, Caterina La Cascia, Craig Morgan, Andrei Szöke, Ilaria Tarricone, Antonio Lasalvia, Diego Quattrone, Els van der Ven, Miguel Bernardo, James B. Kirkbride, Peter B. Jones, Eva Velthorst, Julio Sanjuán, Manuel Arrojo, Domenico Berardi, Charlotte Gayer-Anderson, Jean-Paul Selten, Fabian Termorshuizen, Pierre-Michel Llorca, Robin M. Murray, Hannah E Jongsma, Clinical Developmental Psychology, APH - Mental Health, World Health Organization (WHO) Collaborating Center, Termorshuizen F., Van Der Ven E., Tarricone I., Jongsma H.E., Gayer-Anderson C., Lasalvia A., Tosato S., Quattrone D., La Cascia C., Szoke A., Berardi D., Llorca P.-M., De Haan L., Velthorst E., Bernardo M., Sanjuan J., Arrojo M., Murray R.M., Rutten B.P., Jones P.B., Van Os J., Kirkbride J.B., Morgan C., Selten J.-P., Adult Psychiatry, ANS - Complex Trait Genetics, ANS - Mood, Anxiety, Psychosis, Stress & Sleep, RS: MHeNs - R2 - Mental Health, Psychiatrie & Neuropsychologie, RS: MHeNs - R3 - Neuroscience, and MUMC+: MA Psychiatrie (3)

Subjects
medicine.medical_specialty, Dopamine, Region of origin, Ethnic group, migration, psychosi, stress, 03 medical and health sciences, Race (biology), 0302 clinical medicine, Epidemiology, medicine, Humans, psychosis, 10. No inequality, race, Minority Groups, Applied Psychology, Transients and Migrants, High rate, Incidence, Incidence (epidemiology), Social environment, PREVALENCE, 030227 psychiatry, 3. Good health, Europe, schizophrenia, Psychiatry and Mental health, Geography, Psychotic Disorders, Multinational corporation, 1ST-CONTACT INCIDENCE, ethnicity, epidemiology, 030217 neurology & neurosurgery, SOCIAL DEFEAT HYPOTHESIS, Demography
Abstract

BackgroundIn Europe, the incidence of psychotic disorder is high in certain migrant and minority ethnic groups (hence: ‘minorities’). However, it is unknown how the incidence pattern for these groups varies within this continent. Our objective was to compare, across sites in France, Italy, Spain, the UK and the Netherlands, the incidence rates for minorities and the incidence rate ratios (IRRs, minorities v. the local reference population).MethodsThe European Network of National Schizophrenia Networks Studying Gene–Environment Interactions (EU-GEI) study was conducted between 2010 and 2015. We analyzed data on incident cases of non-organic psychosis (International Classification of Diseases, 10th edition, codes F20–F33) from 13 sites.ResultsThe standardized incidence rates for minorities, combined into one category, varied from 12.2 in Valencia to 82.5 per 100 000 in Paris. These rates were generally high at sites with high rates for the reference population, and low at sites with low rates for the reference population. IRRs for minorities (combined into one category) varied from 0.70 (95% CI 0.32–1.53) in Valencia to 2.47 (95% CI 1.66–3.69) in Paris (test for interaction: p = 0.031). At most sites, IRRs were higher for persons from non-Western countries than for those from Western countries, with the highest IRRs for individuals from sub-Saharan Africa (adjusted IRR = 3.23, 95% CI 2.66–3.93).ConclusionsIncidence rates vary by region of origin, region of destination and their combination. This suggests that they are strongly influenced by the social context.

Published
2020

33. The EUropean Network of National Schizophrenia Networks Studying Gene-Environment Interactions (EU-GEI)

Author

Gayer-Anderson, Charlotte, Jongsma, Hannah E., Di Forti, Marta, Quattrone, Diego, Velthorst, Eva, De Haan, Lieuwe, Selten, Jean-Paul, Szöke, Andrei, Llorca, Pierre-Michel, Tortelli, Andrea, Arango, Celso, Bobes, Julio, Bernardo, Miguel, Sanjuán, Julio, Santos, José Luis, Arrojo, Manuel, Parellada, Mara, Tarricone, Ilaria, Berardi, Domenico, Ruggeri, Mirella, Lasalvia, Antonio, Ferraro, Laura, La Cascia, Caterina, La Barbera, Daniele, Menezes, Paulo Rossi, Del-Ben, Cristina Marta, Rutten, Bart P., Van Os, Jim, Jones, Peter B., Murray, Robin M., Kirkbride, James B., Morgan, Craig, Hubbard, Kathryn, Beards, Stephanie, Reininghaus, Ulrich, Tripoli, Giada, Stilo, Simona A., Roldán, Laura, López, Gonzalo, Matteis, Mario, Rapado, Marta, González, Emiliano, Martínez, Covadonga, Cuadrado, Pedro, Solano, José Juan Rodríguez, Carracedo, Angel, Costas, Javier, Bernardo, Enrique García, Sánchez, Emilio, Olmeda, Ma Soledad, Cabrera, Bibiana, Lorente-Rovira, Esther, Garcia-Portilla, Paz, Jiménez-López, Estela, Franke, Nathalie, Van Dam, Daniella, Termorshuizen, Fabian, Van Der Ven, Elsje, Messchaart, Elles, Leboyer, Marion, Schürhoff, Franck, Baudin, Grégoire, Ferchiou, Aziz, Pignon, Baptiste, Jamain, Stéphane, Richard, Jean-Romain, Charpeaud, Thomas, Tronche, Anne-Marie, Frijda, Flora, Sideli, Lucia, Seminerio, Fabio, Sartorio, Crocettarachele, Marrazzo, Giovanna, Loureiro, Camila Marcelino, Shuhama, Rosana, Tosato, Sarah, Bonetto, Chiara, Cristofalo, Doriana, Gayer-Anderson, Charlotte [0000-0003-1636-889X], Apollo - University of Cambridge Repository, Gayer-Anderson C., Jongsma H.E., Di Forti M., Quattrone D., Velthorst E., de Haan L., Selten J.-P., Szoke A., Llorca P.-M., Tortelli A., Arango C., Bobes J., Bernardo M., Sanjuan J., Santos J.L., Arrojo M., Parellada M., Tarricone I., Berardi D., Ruggeri M., Lasalvia A., Ferraro L., La Cascia C., La Barbera D., Menezes P.R., Del-Ben C.M., Hubbard K., Beards S., Reininghaus U., Tripoli G., Stilo S.A., Roldan L., Lopez G., Matteis M., Rapado M., Gonzalez E., Martinez C., Cuadrado P., Solano J.J.R., Carracedo A., Costas J., Bernardo E.G., Sanchez E., Olmeda M.S., Cabrera B., Lorente-Rovira E., Garcia-Portilla P., Jimenez-Lopez E., Franke N., van Dam D., Termorshuizen F., van der Ven E., Messchaart E., Leboyer M., Schurhoff F., Baudin G., Ferchiou A., Pignon B., Jamain S., Richard J.-R., Charpeaud T., Tronche A.-M., Frijda F., Sideli L., Seminerio F., Sartorio C., Marrazzo G., Loureiro C.M., Shuhama R., Tosato S., Bonetto C., Cristofalo D., Rutten B.P., van Os J., Jones P.B., Murray R.M., Kirkbride J.B., Morgan C., Gayer-Anderson, Charlotte, Jongsma, Hannah E., Di Forti, Marta, Quattrone, Diego, Velthorst, Eva, de Haan, Lieuwe, Selten, Jean-Paul, Szöke, Andrei, Llorca, Pierre-Michel, Tortelli, Andrea, Arango, Celso, Bobes, Julio, Bernardo, Miguel, Sanjuán, Julio, Santos, José Lui, Arrojo, Manuel, Parellada, Mara, Tarricone, Ilaria, Berardi, Domenico, Ruggeri, Mirella, Lasalvia, Antonio, Ferraro, Laura, La Cascia, Caterina, La Barbera, Daniele, Menezes, Paulo Rossi, Del-Ben, Cristina Marta, Rutten, Bart P., van Os, Jim, Jones, Peter B., Murray, Robin M., Kirkbride, James B., Morgan, Craig, Psychiatrie & Neuropsychologie, RS: MHeNs - R2 - Mental Health, MUMC+: MA Psychiatrie (3), RS: MHeNs - R3 - Neuroscience, MUMC+: Hersen en Zenuw Centrum (3), ANS - Mood, Anxiety, Psychosis, Stress & Sleep, Adult Psychiatry, and APH - Mental Health

Subjects
Male, Health (social science), Epidemiology, Ethnic group, Ethnic Group, Gene-environment interactions, Environment–environment interactions, 0302 clinical medicine, Ethnicity, 10. No inequality, First episode, RISK, biology, Incidence (epidemiology), Incidence, CANNABIS, Middle Aged, Case-control, First-episode psychosis, 3. Good health, Europe, Psychiatry and Mental health, Case–control Environment–environment interactions EU-GEI First-episode psychosis Gene–environment interactions Incidence, Case–control, EU-GEI, Gene–environment interactions, Schizophrenia, Cohort, Female, Psychology, Case-Control Studie, Brazil, Human, Adult, medicine.medical_specialty, Social Psychology, Adolescent, Study Protocols and Samples, DISORDERS, Environment–environment interaction, Representativeness heuristic, 03 medical and health sciences, Young Adult, PSYCHOSIS, AGE, First-episode psychosi, Environment-environment interactions, medicine, Humans, Gene–environment interaction, Settore MED/25 - Psichiatria, METAANALYSIS, biology.organism_classification, medicine.disease, 030227 psychiatry, Case-Control Studies, Gene-Environment Interaction, Cannabis, CHILDHOOD ADVERSITIES, 030217 neurology & neurosurgery, Demography
Abstract

Funder: FP7 Ideas: European Research Council; doi: http://dx.doi.org/10.13039/100011199; Grant(s): HEALTH-F2-2010-241909, Purpose: The EUropean Network of National Schizophrenia Networks Studying Gene–Environment Interactions (EU-GEI) study contains an unparalleled wealth of comprehensive data that allows for testing hypotheses about (1) variations in incidence within and between countries, including by urbanicity and minority ethnic groups; and (2) the role of multiple environmental and genetic risk factors, and their interactions, in the development of psychotic disorders. Methods: Between 2010 and 2015, we identified 2774 incident cases of psychotic disorders during 12.9 million person-years at risk, across 17 sites in 6 countries (UK, The Netherlands, France, Spain, Italy, and Brazil). Of the 2774 incident cases, 1130 cases were assessed in detail and form the case sample for case–control analyses. Across all sites, 1497 controls were recruited and assessed. We collected data on an extensive range of exposures and outcomes, including demographic, clinical (e.g. premorbid adjustment), social (e.g. childhood and adult adversity, cannabis use, migration, discrimination), cognitive (e.g. IQ, facial affect processing, attributional biases), and biological (DNA via blood sample/cheek swab). We describe the methodology of the study and some descriptive results, including representativeness of the cohort. Conclusions: This resource constitutes the largest and most extensive incidence and case–control study of psychosis ever conducted.

Published
2020

34. Use of multiple polygenic risk scores for distinguishing schizophrenia-spectrum disorder and affective psychosis categories in a first-episode sample; the EU-GEI study

Author

Victoria Rodriguez, Luis Alameda, Diego Quattrone, Giada Tripoli, Charlotte Gayer-Anderson, Edoardo Spinazzola, Giulia Trotta, Hannah E. Jongsma, Simona Stilo, Caterina La Cascia, Laura Ferraro, Daniele La Barbera, Antonio Lasalvia, Sarah Tosato, Ilaria Tarricone, Elena Bonora, Stéphane Jamain, Jean-Paul Selten, Eva Velthorst, Lieuwe de Haan, Pierre-Michel Llorca, Manuel Arrojo, Julio Bobes, Miguel Bernardo, Celso Arango, James Kirkbride, Peter B. Jones, Bart P. Rutten, Alexander Richards, Pak C. Sham, Michael O'Donovan, Jim Van Os, Craig Morgan, Marta Di Forti, Robin M. Murray, Evangelos Vassos, Adult Psychiatry, APH - Mental Health, Amsterdam Neuroscience - Complex Trait Genetics, Amsterdam Neuroscience - Mood, Anxiety, Psychosis, Stress & Sleep, Rodriguez, V, Alameda, L, Quattrone, D, Tripoli, G, Gayer-Anderson, C, Spinazzola, E, Trotta, G, Jongsma, HE, Stilo, S, La Cascia, C, Ferraro, L, La Barbera, D, Lasalvia, A, Tosato, S, Tarricone, I, Bonora, E, Jamain, S, Selten, JP, Velthorst, E, de Haan, L, Llorca, PM, Arrojo, M, Bobes, J, Bernardo, M, Arango, C, Kirkbride, J, Jones, PB, Rutten, BP, Richards, A, Sham, PC, O'Donovan, M, Van Os, J, Morgan, C, Di Forti, M, Murray, RM, Vassos, E, Psychiatrie & Neuropsychologie, RS: MHeNs - R2 - Mental Health, RS: MHeNs - R3 - Neuroscience, and MUMC+: MA Psychiatrie (3)

Subjects
bipolar disorder, Affective psychosis, diagnosis, GENETIC-RELATIONSHIPS, schizophrenia-spectrum disorder, Psychiatry and Mental health, Affective psychosis, bipolar disorder, diagnosis, genetics, polygenic score, psychosis, psychotic depression, schizophrenia-spectrum disorder, LIABILITY, psychotic depression, genetics, polygenic score, psychosis, GENOME-WIDE ASSOCIATION, Applied Psychology
Abstract

This work was supported by funding from the European Community’s Seventh Framework Programme under grant agreement No. HEALTH-F2-2010-241909 (Project EU-GEI). (...) CA was supported by the Spanish Ministry of Science and Innovation; Instituto de Salud Carlos III (SAM16PE07CP1, PI16/02012, PI19/024), co-financed by ERDF Funds from the European Commission, ‘A way of making Europe’, CIBERSAM. Madrid Regional Government (B2017/BMD-3740 AGES-CM-2), Fundación Familia Alonso and Fundación Alicia Koplowitz. MB was supported by the Ministry of Economy and Competitivity (PI08/0208; PI11/00325; PI14/00612), Instituto de Salud Carlos III – ERDF Funds from the European Commission, ‘A way of making Europe’, CIBERSAM, by the CERCA Programme/Generalitat de Catalunya and Secretaria d’Universitats i Recerca del Departament d’Economia I Coneixement (2017SGR1355). Departament de Salut de la Generalitat de Catalunya, en la convocatoria corresponent a l’any 2017 de concessió de subvencions del PERIS 2016-2020, modalitat Projectes de recerca orientats a l’atenció primària, amb el codi d’expedient SLT006/17/00345; and grateful for the support of the Institut de Neurociències, Universitat de Barcelona., Rodriguez V., Alameda L., Quattrone D., Tripoli G., Gayer-Anderson C., Spinazzola E., Trotta G., Jongsma H.E., Stilo S., La Cascia C., Ferraro L., La Barbera D., Lasalvia A., Tosato S., Tarricone I., Bonora E., Jamain S., Selten J.-P., Velthorst E., De Haan L., Llorca P.-M., Arrojo M., Bobes J., Bernardo M., Arango C., Kirkbride J., Jones P.B., Rutten B.P., Richards A., Sham P.C., O'Donovan M., Van Os J., Morgan C., Di Forti M., Murray R.M., Vassos E.

Published
2022

35. The relationship of symptom dimensions with premorbid adjustment and cognitive characteristics at first episode psychosis: Findings from the EU-GEI study

Author

James B. Kirkbride, Hannah E. Jongsma, Alastair G. Cardno, Paulo Rossi Menezes, Andrea Quattrone, Pierre-Michel Llorca, Jose Luis Santos, Ilaria Tarricone, F. Seminerio, Charlotte Gayer-Anderson, Lucia Sideli, Roberto Muratori, Daniele La Barbera, G Tripoli, Teresa Sánchez-Gutiérrez, Jim van Os, Bart P. F. Rutten, Miguel Bernardo, Marta Di Forti, Robin M. Murray, Sarah Tosato, Julio Sanjuán, Lieuwe de Haan, Manuel Arrojo, Crocettarachele Sartorio, Eva Velthorst, Andrei Szöke, Antonio Lasalvia, Julio Bobes, Diego Quattrone, Craig Morgan, Ulrich Reininghaus, Victoria Rodriguez, Evangelos Vassos, Jean-Paul Selten, Giovanna Marrazzo, Caterina La Cascia, Celso Arango, Cristina Marta Del-Ben, Andrea Tortelli, Laura Ferraro, Peter B. Jones, RS: MHeNs - R3 - Neuroscience, Psychiatrie & Neuropsychologie, MUMC+: MA Psychiatrie (3), RS: MHeNs - R2 - Mental Health, Università degli studi di Palermo - University of Palermo, Faculty of Health Science, Universidad Internacional de la Rioja (UNIR), Universidad Complutense de Madrid = Complutense University of Madrid [Madrid] (UCM), Department of Psychiatry, Psychiatric Genetic Group, Instituto de Investigación Sanitaria de Santiago de Compostela, Complejo Hospitalario Universitario de Santiago de Compostela, Barcelona Clinic Schizophrenia Unit, Department of Medicine, Neuroscience Institute, Hospital clinic, University of Barcelona, IDIBAPS, CIBERSAM, Department of Medicine, Psychiatry Area, School of Medicine, Universidad de Oviedo, Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Universidade de São Paulo Medical School (FMUSP), Department of Health Service and Population Research, Institute of Psychiatry, King's College London, Psylife Group, Division of Psychiatry, University College London, 6th Floor, Maple House, Section of Psychiatry, Azienda Ospedaliera Universitaria Integrata di Verona, Università degli studi di Verona = University of Verona (UNIVR), Institut Pascal (IP), Centre National de la Recherche Scientifique (CNRS)-Université Clermont Auvergne (UCA)-Institut national polytechnique Clermont Auvergne (INP Clermont Auvergne), Université Clermont Auvergne (UCA)-Université Clermont Auvergne (UCA), Department of Preventive Medicine, Faculdade de Medicina, Universidade of São Paulo, Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, South Limburg Mental Health Research and Teaching Network, Maastricht University Medical Centre, Department of Psychiatry, Servicio de Psiquiatría Hospital 'Virgen de la Luz', Universitat de València (UV), Rivierduinen Institute for Mental Health Care, Institut National de la Santé et de la Recherche Médicale (INSERM), Alma Mater Studiorum Università di Bologna [Bologna] (UNIBO), Dapertment of Mental Health and pathological addictions, Bologna Local Health Authority, Etablissement Public de Santé Maison Blanche, Department of Psychiatry, Early Psychosis Section, Amsterdam UMC, University of Amsterdam, Department of Psychiatry, Icahn School of Medicine at Mount Sinai, Department of Psychosis Studies, Institute of Psychiatry, Psychology, and Neuroscience, King's College London, National Health Service, Villa Betania Institute, Department of Psychiatry, University of Cambridge, Cambridge, UK, Department Psychiatry, Brain Centre Rudolf Magnus, Utrecht University Medical Centre, Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College London, Department of Psychiatry, Early Psychosis Section, Academic Medical Centre, University of Amsterdam, Institute of Cognitive and Clinical Neuroscience, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, University of Leeds, South London and Maudsley NHS Mental Health Foundation Trust, Tournayre, Christophe, Ferraro L., La Cascia C., La Barbera D., Sanchez-Gutierrez T., Tripoli G., Seminerio F., Sartorio C., Marrazzo G., Sideli L., Arango C., Arrojo M., Bernardo M., Bobes J., Del-Ben C.M., Gayer-Anderson C., Jongsma H.E., Kirkbride J.B., Lasalvia A., Tosato S., Llorca P.-M., Menezes P.R., Rutten B.P., Santos J.L., Sanjuan J., Selten J.-P., Szoke A., Tarricone I., Muratori R., Tortelli A., Velthorst E., Rodriguez V., Quattrone A., Jones P.B., Van Os J., Vassos E., Morgan C., de Haan L., Reininghaus U., Cardno A.G., Di Forti M., Murray R.M., Quattrone D., Jones, Peter [0000-0002-0387-880X], Apollo - University of Cambridge Repository, University College of London [London] (UCL), University of Cambridge [UK] (CAM), Adult Psychiatry, APH - Mental Health, Amsterdam Neuroscience - Complex Trait Genetics, and Amsterdam Neuroscience - Mood, Anxiety, Psychosis, Stress & Sleep

Subjects
Psychosis, First episode psychosis, cognitive domains, Premorbid Adjustment Scale, QUOCIENTE DE INTELIGÊNCIA, Transdiagnostic Premorbid adjustment, NEGATIVE SYMPTOMS, Article, symptom dimensions, premorbid adjustment, WORKING-MEMORY, Secondary analysis, first episode psychosis, 1ST-EPISODE NONAFFECTIVE PSYCHOSIS, Medicine, Scopus, Cognitive domain, [SDV.NEU] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC], Settore MED/25 - Psichiatria, Biological Psychiatry, Transdiagnostic, business.industry, Working memory, Confounding, Cognitive domains, Cognition, BIPOLAR DISORDER, Symptom dimensions, medicine.disease, GENE-ENVIRONMENT INTERACTIONS, First episode psychosi, CANNABIS USE, Psychiatry and Mental health, Symptom dimension, Perceptual reasoning, JCR, IQ, SOCIAL COGNITION, transdiagnostic, PROCESSING-SPEED, NEURODEVELOPMENTAL TRAJECTORIES, [SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC], Premorbid adjustment, business, SCHIZOAFFECTIVE DISORDER, Clinical psychology
Abstract

Premorbid functioning and cognitive measures may reflect gradients of developmental impairment across diagnostic categories in psychosis. In this study, we sought to examine the associations of current cognition and premorbid adjustment with symptom dimensions in a large first episode psychosis (FEP) sample. We used data from the international EU-GEI study. Bifactor modelling of the Operational Criteria in Studies of Psychotic Illness (OPCRIT) ratings provided general and specific symptom dimension scores. Premorbid Adjustment Scale estimated premorbid social (PSF) and academic adjustment (PAF), and WAIS-brief version measured IQ. A MANCOVA model examined the relationship between symptom dimensions and PSF, PAF, and IQ, having age, sex, country, self-ascribed ethnicity and frequency of cannabis use as confounders. In 785 patients, better PSF was associated with fewer negative (B=-0.12, 95% C.I. -0.18, -0.06, p

Published
2021

36. Migration history and risk of psychosis: results from the multinational EU-GEI study

Author

Iulio Sanjuán, Robin M. Murray, Els van der Ven, James B. Kirkbride, Hannah E Jongsma, Jean-Paul Selten, Manuel Arrojo, Julio Bobes, Andrei Szöke, Cristina Marta Del-Ben, Roberto Muratori, Jim van Os, Mara Parellada, Bart P. F. Rutten, Craig Morgan, Pierre-Michel Llorca, Marta Di Forti, Sarah Tosato, Peter B. Jones, Miguel Bernardo, Ilaria Tarricone, Simona A. Stilo, Jose Luis Santos, Federico Suprani, Conrad Iyegbe, Giuseppe D’Andrea, Eva Velthorst, Domenico Berardi, Paulo Rossi Menezes, Andrea Tortelli, Laura Ferraro, Antonio Lasalvia, Diego Quattrone, Caterina La Cascia, Celso Arango, Lieuwe de Haan, Charlotte Gayer-Anderson, Giada Tripoli, University of Bologna/Università di Bologna, Alma Mater Studiorum Università di Bologna [Bologna] (UNIBO), University College of London [London] (UCL), University of Cambridge [UK] (CAM), Università degli studi di Verona = University of Verona (UNIVR), King‘s College London, Institute of Psychiatry, Psychology & Neuroscience, King's College London, Columbia University [New York], Department of Psychiatry and Neuropsychology [Maastricht], Maastricht University [Maastricht], VU University Medical Center [Amsterdam], Icahn School of Medicine at Mount Sinai [New York] (MSSM), Universidade de São Paulo = University of São Paulo (USP), Hospital General Universitario 'Gregorio Marañón' [Madrid], Centro de Investigación Biomédica en Red Salud Mental [Madrid] (CIBER-SAM), Universidad Complutense de Madrid = Complutense University of Madrid [Madrid] (UCM), Università degli studi di Palermo - University of Palermo, Universidad de Oviedo [Oviedo], University of Barcelona, Complejo Hospitalario Universitario de Santiago de Compostela [Saint-Jacques-de-Compostelle, Espagne] (CHUS), Instituto de Investigación Sanitaria de Santiago de Compostela / Health Research Institute of Santiago de Compostela (IDIS), Institut Pascal (IP), Centre National de la Recherche Scientifique (CNRS)-Université Clermont Auvergne (UCA)-Institut national polytechnique Clermont Auvergne (INP Clermont Auvergne), Université Clermont Auvergne (UCA)-Université Clermont Auvergne (UCA), Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Centre d'Investigation Clinique Henri Mondor (CIC Henri Mondor), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), University Medical Center [Utrecht], Cambridgeshire & Peterborough NHS Foundation Trust [Cambridge] (CPFT), RS: MHeNs - R2 - Mental Health, Psychiatrie & Neuropsychologie, MUMC+: MA Psychiatrie (3), RS: MHeNs - R3 - Neuroscience, Adult Psychiatry, APH - Mental Health, ANS - Complex Trait Genetics, ANS - Mood, Anxiety, Psychosis, Stress & Sleep, Tarricone I., D'Andrea G., Jongsma H.E., Tosato S., Gayer-Anderson C., Stilo S.A., Suprani F., Iyegbe C., Van Der Ven E., Quattrone D., Di Forti M., Velthorst E., Rossi Menezes P., Arango C., Parellada M., Lasalvia A., La Cascia C., Ferraro L., Bobes J., Bernardo M., Sanjuan I., Santos J.L., Arrojo M., Del-Ben C.M., Tripoli G., Llorca P.-M., De Haan L., Selten J.-P., Tortelli A., Szoke A., Muratori R., Rutten B.P., Van Os J., Jones P.B., Kirkbride J.B., Berardi D., Murray R.M., Morgan C., Clinical Developmental Psychology, World Health Organization (WHO) Collaborating Center, and Tournayre, Christophe

Subjects
Psychosis, medicine.medical_specialty, ESTUDOS DE CASOS E CONTROLES, Ethnic group, Logistic regression, IMMIGRANTS, FAMILY-HISTORY, first-generation migrants, Odds, 03 medical and health sciences, 0302 clinical medicine, First-episode psychosi, first-generation migrant, SCHIZOPHRENIA, medicine, migration adversities, [SDV.NEU] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC], 1ST-EPISODE PSYCHOSIS, INTERNAL MIGRATION, Applied Psychology, Cumulative effect, ComputingMilieux_MISCELLANEOUS, migration history, psychosis risk, business.industry, Public health, migration adversitie, SDG 10 - Reduced Inequalities, First-episode psychosis, medicine.disease, CHILDHOOD TRAUMA, 030227 psychiatry, 3. Good health, ETHNICITY, Psychiatry and Mental health, social disadvantages, Schizophrenia, Multinational corporation, 1ST-CONTACT INCIDENCE, [SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC], business, MENTAL-HEALTH, SOCIAL DISADVANTAGE, 030217 neurology & neurosurgery, Demography
Abstract

The European Network of National Schizophrenia Networks Studying Gene-Environment Interactions (EU-GEI) Project was funded by grant agreement Health-F2-2010-241909 (Project EU-GEI) from the European Community’s Seventh Framework programme., Tarricone, I., D'Andrea, G., Jongsma, H.E., Tosato, S., Gayer-Anderson, C., Stilo, S.A., Suprani, F., Iyegbe, C., Van Der Ven, E., Quattrone, D., Di Forti, M., Velthorst, E., Rossi Menezes, P., Arango, C., Parellada, M., Lasalvia, A., La Cascia, C., Ferraro, L., Bobes, J., Bernardo, M., Sanjuán, I., Santos, J.L., Arrojo, M., Del-Ben, C.M., Tripoli, G., Llorca, P.-M., De Haan, L., Selten, J.-P., Tortelli, A., Szöke, A., Muratori, R., Rutten, B.P., Van Os, J., Jones, P.B., Kirkbride, J.B., Berardi, D., Murray, R.M., Morgan, C.

Published
2021

37. Social disadvantage, linguistic distance, ethnic minority status and first-episode psychosis: Results from the EU-GEI case-control study

Author

Robin M. Murray, Hannah E Jongsma, Ilaria Tarricone, Els van der Ven, Domenico Berardi, Julio Bobes, Andrei Szöke, Antonio Lasalvia, Diego Quattrone, Peter B. Jones, Manuel Arrojo, Jose Luis Santos, Lieuwe de Haan, Craig Morgan, Caterina La Cascia, Miguel Bernardo, Celso Arango, Marta Di Forti, Julio Sanjuán, Andrea Tortelli, Paulo Rossi Menezes, Charlotte Gayer-Anderson, Christina Marta Del-Ben, Eva Velthorst, James B. Kirkbride, Jim van Os, Bart P. F. Rutten, Jongsma H.E., Gayer-Anderson C., Tarricone I., Velthorst E., Van Der Ven E., Quattrone D., Di Forti M., Menezes P.R., Del-Ben C.M., Arango C., Lasalvia A., Berardi D., La Cascia C., Bobes J., Bernardo M., Sanjuan J., Santos J.L., Arrojo M., De Haan L., Tortelli A., Szoke A., Murray R.M., Rutten B.P., Van Os J., Morgan C., Jones P.B., Kirkbride J.B., ANS - Mood, Anxiety, Psychosis, Stress & Sleep, Adult Psychiatry, APH - Mental Health, Clinical Developmental Psychology, RS: MHeNs - R2 - Mental Health, Psychiatrie & Neuropsychologie, RS: MHeNs - R3 - Neuroscience, MUMC+: MA Psychiatrie (3), and MUMC+: Hersen en Zenuw Centrum (3)

Subjects
Male, Social Determinants of Health, Ethnic group, Poison control, IMMIGRANTS, Occupational safety and health, 0302 clinical medicine, psychotic disorders, SCHIZOPHRENIA, Discrimination, Odds Ratio, Applied Psychology, RISK, HYPOTHESIS, Communication Barriers, Linguistic distance, Middle Aged, epidemiology, ethnicity, social disadvantage, 3. Good health, Social research, Europe, Psychiatry and Mental health, MIGRANT GROUPS, Female, STRIATAL DOPAMINE FUNCTION, Adult, Adolescent, DISORDERS, 1ST EPISODE, Black People, Library science, TRANSTORNOS PSICÓTICOS, White People, Young Adult, 03 medical and health sciences, First episode psychosis, Political science, Humans, Minority status, INCIDENCE RATES, Health Status Disparities, Original Articles, psychotic disorder, 030227 psychiatry, Case-Control Studies, Ethnic and Racial Minorities, IDENTITY, Gene-Environment Interaction, Social disadvantage, 030217 neurology & neurosurgery
Abstract

The European Network of National Schizophrenia Networks Studying Gene-Environment Interactions (EU-GEI) Project was funded by grant agreement Health-F2-2010-241909 (Project EU-GEI) from the European Community’s Seventh Framework programme. The Brazilian study was funded by grant 2012-0417-0 from the São Paulo Research Foundation. Dr Jongsma is funded by the Economic and Social Research Council (grant ES/S011714/1). Dr Kirkbride is funded by the Wellcome Trust and Royal Society (Grant 101272/Z/13/Z). Dr Jongsma and Professor Jones are funded by the National Institute of Health Research Collaboration of Leadership in Applied Health Research and Care East of England. Professor Rutten is funded by the Netherlands Scientific Organisation (VIDI award number 91718336). Dr Jongsma and Dr Kirkbride are supported by the National Institute for Health Research, University College London Hospital, Biomedical Research Centre., Jongsma, H.E., Gayer-Anderson, C., Tarricone, I., Velthorst, E., Van Der Ven, E., Quattrone, D., Di Forti, M., Menezes, P.R., Del-Ben, C.M., Arango, C., Lasalvia, A., Berardi, D., La Cascia, C., Bobes, J., Bernardo, M., Sanjuán, J., Santos, J.L., Arrojo, M., De Haan, L., Tortelli, A., Szöke, A., Murray, R.M., Rutten, B.P., Van Os, J., Morgan, C., Jones, P.B., Kirkbride, J.B.

Published
2021

38. Synergistic effects of childhood adversity and polygenic risk in first-episode psychosis

Author

Robin M. Murray, Luis Alameda, Andrea Tortelli, Laura Ferraro, Cristina Marta Del-Ben, Eva Velthorst, Peter B. Jones, Monica Aas, James B. Kirkbride, Pierre-Michel Llorca, Evangelos Vassos, Hannah E. Jongsma, Paola Dazzan, Jean-Paul Selten, Miguel Bernardo, Victoria Rodriguez, Lieuwe de Haan, Marta Di Forti, Jose Luis Santos, Roberto Muratori, Caterina La Cascia, Manuel Arrojo, Pak C. Sham, Jim van Os, Bart P. F. Rutten, Daniele La Barbera, Celso Arango, Ilaria Tarricone, Domenico Berardi, Sarah Tosato, Craig Morgan, Julio Bobes, Paulo Rossi Menezes, Antonella Trotta, Julio Sanjuán, Andrei Szöke, Antonio Lasalvia, Diego Quattrone, Charlotte Gayer-Anderson, Giada Tripoli, Aas M., Alameda L., Di Forti M., Quattrone D., Dazzan P., Trotta A., Ferraro L., Rodriguez V., Vassos E., Sham P., Tripoli G., La Cascia C., La Barbera D., Tarricone I., Muratori R., Berardi D., Lasalvia A., Tosato S., Szoke A., Llorca P.-M., Arango C., Tortelli A., De Haan L., Velthorst E., Bobes J., Bernardo M., Sanjuan J., Santos J.L., Arrojo M., Del-Ben C.M., Menezes P.R., Selten J.-P., Jones P.B., Jongsma H.E., Kirkbride J.B., Rutten B.P.F., Van Os J., Gayer-Anderson C., Murray R.M., Morgan C., Cascia C.L., Barbera D.L., RS: MHeNs - R3 - Neuroscience, Psychiatrie & Neuropsychologie, MUMC+: MA Psychiatrie (3), RS: MHeNs - R2 - Mental Health, MUMC+: Hersen en Zenuw Centrum (3), Adult Psychiatry, APH - Mental Health, ANS - Complex Trait Genetics, and ANS - Mood, Anxiety, Psychosis, Stress & Sleep

Subjects
SCHIZOPHRENIA SPECTRUM, medicine.medical_specialty, GENES, polygenic risk, first-episode psychosi, ILLNESS, interaction contrast ratio, Childhood trauma, DOPAMINE, First episode psychosis, Settore MED/48 -Scienze Infermierist. e Tecn. Neuro-Psichiatriche e Riabilitat, MALTREATMENT, Medicine, first-episode psychosis, ABUSE, Psychiatry, Settore MED/25 - Psichiatria, Applied Psychology, TRAUMA, ENVIRONMENT, business.industry, medicine.disease, schizophrenia, Psychiatry and Mental health, Schizophrenia, RELIABILITY, Polygenic risk score, synergistic effects, business
Abstract

The European Network of National Schizophrenia Networks Studying Gene-Environment Interactions (EU-GEI) Project is funded by grant agreement HEALTH-F2-2010-241909 (Project EU-GEI) from the European Community’s Seventh Framework Programme., Aas, M; Alameda, L; Di Forti, M; Quattrone, D; Dazzan, P; Trotta, A; Ferraro, L; Rodriguez, V; Vassos, E; Sham, P; Tripoli, G; La Cascia, C; La Barbera, D; Tarricone, I; Muratori, R; Berardi, D; Lasalvia, A; Tosato, S; Szoke, A; Llorca, PM; Arango, C; Tortelli, A; de Haan, L; Velthorst, E; Bobes, J; Bernardo, M; Sanjuan, J; Santos, JL; Arrojo, M; Del-Ben, CM; Menezes, PR; Selten, JP; Jones, PB; Jongsma, HE; Kirkbride, JB; Rutten, BPF; van Os, J; Gayer-Anderson, C; Murray, RM; Morgan, C

Published
2021

39. The continuity of effect of schizophrenia polygenic risk score and patterns of cannabis use on transdiagnostic symptom dimensions at first-episode psychosis: findings from the EU-GEI study

Author

Quattrone, Diego, Reininghaus, Ulrich, Richards, Alex L., Tripoli, Giada, Ferraro, Laura, Quattrone, Andrea, Marino, Paolo, Rodriguez, Victoria, Spinazzola, Edoardo, Gayer-Anderson, Charlotte, Jongsma, Hannah E., Jones, Peter B., La Cascia, Caterina, La Barbera, Daniele, Tarricone, Ilaria, Bonora, Elena, Tosato, Sarah, Lasalvia, Antonio, Szöke, Andrei, Arango, Celso, Bernardo, Miquel, Bobes, Julio, Del Ben, Cristina Marta, Menezes, Paulo Rossi, Llorca, Pierre-Michel, Santos, Jose Luis, Sanjuán, Julio, Arrojo, Manuel, Tortelli, Andrea, Velthorst, Eva, Berendsen, Steven, de Haan, Lieuwe, Rutten, Bart P. F., Lynskey, Michael T., Freeman, Tom P., Kirkbride, James B., Sham, Pak C., O'Donovan, Michael C., Cardno, Alastair G., Vassos, Evangelos, van Os, Jim, Morgan, Craig, Murray, Robin M., Lewis, Cathryn M., Di Forti, Marta, Hubbard, Kathryn, Beards, Stephanie, Stilo, Simona A., Parellada, Mara, Fraguas, David, Castro, Marta Rapado, Andreu-Bernabeu, Álvaro, López, Gonzalo, Matteis, Mario, González, Emiliano, Durán-Cutilla, Manuel, Díaz-Caneja, Covadonga M., Cuadrado, Pedro, Rodríguez Solano, José Juan, Carracedo, Angel, Costas, Javier, Sánchez, Emilio, Amoretti, Silvia, Lorente-Rovira, Esther, Garcia-Portilla, Paz, Jiménez-López, Estela, Franke, Nathalie, van Dam, Daniella, Termorshuizen, Fabian, van der Ven, Elsje, Messchaart, Elles, Leboyer, Marion, Schu?rhoff, Franck, Jamain, Stéphane, Baudin, Grégoire, Ferchiou, Aziz, Pignon, Baptiste, Richard, Jean-Romain, Charpeaud, Thomas, Tronche, Anne-Marie, Frijda, Flora, Marrazzo, Giovanna, Sideli, Lucia, Sartorio, Crocettarachele, Seminerio, Fabio, Loureiro, Camila Marcelino, Shuhama, Rosana, Ruggeri, Mirella, Bonetto, Chiara, Cristofalo, Doriana, Berardi, Domenico, Seri, Marco, D?Andrea, Giuseppe, Psychiatrie & Neuropsychologie, RS: MHeNs - R2 - Mental Health, RS: MHeNs - R3 - Neuroscience, MUMC+: MA Psychiatrie (3), MUMC+: Hersen en Zenuw Centrum (3), Quattrone D., Reininghaus U., Richards A.L., Tripoli G., Ferraro L., Quattrone A., Marino P., Rodriguez V., Spinazzola E., Gayer-Anderson C., Jongsma H.E., Jones P.B., La Cascia C., La Barbera D., Tarricone I., Bonora E., Tosato S., Lasalvia A., Szoke A., Arango C., Bernardo M., Bobes J., Del Ben C.M., Menezes P.R., Llorca P.-M., Santos J.L., Sanjuan J., Arrojo M., Tortelli A., Velthorst E., Berendsen S., de Haan L., Rutten B.P.F., Lynskey M.T., Freeman T.P., Kirkbride J.B., Sham P.C., O'Donovan M.C., Cardno A.G., Vassos E., van Os J., Morgan C., Murray R.M., Lewis C.M., Di Forti M., Hubbard K., Beards S., Stilo S.A., Parellada M., Fraguas D., Castro M.R., Andreu-Bernabeu A., Lopez G., Matteis M., Gonzalez E., Duran-Cutilla M., Diaz-Caneja C.M., Cuadrado P., Rodriguez Solano J.J., Carracedo A., Costas J., Sanchez E., Amoretti S., Lorente-Rovira E., Garcia-Portilla P., Jimenez-Lopez E., Franke N., van Dam D., Termorshuizen F., van der Ven E., Messchaart E., Leboyer M., Schurhoff F., Jamain S., Baudin G., Ferchiou A., Pignon B., Richard J.-R., Charpeaud T., Tronche A.-M., Frijda F., Marrazzo G., Sideli L., Sartorio C., Seminerio F., Loureiro C.M., Shuhama R., Ruggeri M., Bonetto C., Cristofalo D., Berardi D., Seri M., D'Andrea G., Quattrone, Diego [0000-0002-6051-8309], Richards, Alex L [0000-0003-3218-7247], Marino, Paolo [0000-0003-3571-1753], Rodriguez, Victoria [0000-0003-0383-0846], Jones, Peter B [0000-0002-0387-880X], Tosato, Sarah [0000-0002-9665-7538], Bernardo, Miquel [0000-0001-8748-6717], Bobes, Julio [0000-0003-2187-4033], Del Ben, Cristina Marta [0000-0003-0145-9975], Menezes, Paulo Rossi [0000-0001-6330-3314], Llorca, Pierre-Michel [0000-0001-7438-8990], Rutten, Bart PF [0000-0002-9834-6346], Kirkbride, James B [0000-0003-3401-0824], O'Donovan, Michael C [0000-0001-7073-2379], Vassos, Evangelos [0000-0001-6363-0438], Murray, Robin M [0000-0003-0829-0519], Lewis, Cathryn M [0000-0002-8249-8476], Apollo - University of Cambridge Repository, Rutten, Bart P F [0000-0002-9834-6346], Adult Psychiatry, APH - Mental Health, ANS - Complex Trait Genetics, and ANS - Mood, Anxiety, Psychosis, Stress & Sleep

Subjects
medicine.medical_specialty, Psychosis, Population, Neurosciences. Biological psychiatry. Neuropsychiatry, PHENOTYPES, ILLNESS, Psychotic Disorder, Predictive markers, Article, Cellular and Molecular Neuroscience, DEFICIT SYNDROME, Risk Factors, First episode psychosis, medicine, Settore MED/48 -Scienze Infermierist. e Tecn. Neuro-Psichiatriche e Riabilitat, Humans, Cannabi, Clinical genetics, Genetic risk, VALIDITY, education, Settore MED/25 - Psichiatria, SCHEDULE, Biological Psychiatry, METAANALYSIS, Cannabis, UTILITY, education.field_of_study, Risk Factor, ESQUIZOFRENIA, ASSOCIATION, Cannabis use, medicine.disease, BIFACTOR MODEL, Psychiatry and Mental health, Psychotic Disorders, INTERRATER RELIABILITY, Schizophrenia, Linear Models, Linear Model, Medical genetics, Polygenic risk score, Psychology, Human, RC321-571, Clinical psychology
Abstract

The work was supported by Guarantors of Brain post-doctoral clinical fellowship to DQ; Clinician Scientist Medical Research Council fellowship (project reference MR/M008436/1) to MDF; Heisenberg professorship from the German Research Founda- tion (grant no. 389624707) to UR; the National Institute for Health Research (NIHR) Maudsley Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King’s College London. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care. The EU-GEI Project is funded by the European Community’s Seventh Framework Programme under grant agreement No. HEALTH-F2-2010-241909 (Project EU-GEI). The Brazilian study was funded by the São Paulo Research Foundation under grant number 2012/0417-0., Quattrone D., Reininghaus U., Richards A.L., Tripoli G., Ferraro L., Quattrone A., Marino P., Rodriguez V., Spinazzola E., Gayer-Anderson C., Jongsma H.E., Jones P.B., La Cascia C., La Barbera D., Tarricone I., Bonora E., Tosato S., Lasalvia A., Szöke A., Arango C., Bernardo M., Bobes J., Del Ben C.M., Menezes P.R., Llorca P.-M., Santos J.L., Sanjuán J., Arrojo M., Tortelli A., Velthorst E., Berendsen S., de Haan L., Rutten B.P.F., Lynskey M.T., Freeman T.P., Kirkbride J.B., Sham P.C., O’Donovan M.C., Cardno A.G., Vassos E., van Os J., Morgan C., Murray R.M., Lewis C.M., Di Forti M., Hubbard K., Beards S., Stilo S.A., Parellada M., Fraguas D., Castro M.R., Andreu-Bernabeu Á., López G., Matteis M., González E., Durán-Cutilla M., Díaz-Caneja C.M., Cuadrado P., Rodríguez Solano J.J., Carracedo A., Costas J., Sánchez E., Amoretti S., Lorente-Rovira E., Garcia-Portilla P., Jiménez-López E., Franke N., van Dam D., Termorshuizen F., van der Ven E., Messchaart E., Leboyer M., Schürhoff F., Jamain S., Baudin G., Ferchiou A., Pignon B., Richard J.-R., Charpeaud T., Tronche A.-M., Frijda F., Marrazzo G., Sideli L., Sartorio C., Seminerio F., Loureiro C.M., Shuhama R., Ruggeri M., Bonetto C., Cristofalo D., Berardi D., Seri M., D’Andrea G.

Published
2021

40. Pre-training inter-rater reliability of clinical instruments in an international psychosis research project

Author

Steven Berendsen, Pim Kapitein, Frederike Schirmbeck, Mirjam J. van Tricht, Philip McGuire, Craig Morgan, Charlotte Gayer-Anderson, Matthew J. Kempton, Lucia Valmaggia, Diego Quattrone, Marta di Forti, Mark van der Gaag, James B. Kirkbride, Hannah E. Jongsma, Peter B. Jones, Maria Parellada, Celso Arango, Manuel Arrojo, Miguel Bernardo, Julio Sanjuán, José Luis Santos, Andrei Szöke, Andrea Tortelli, Pierre-Michel Llorca, Ilaria Tarricone, Giada Tripoli, Laura Ferraro, Caterina La Cascia, Antonio Lasalvia, Sarah Tosato, Paulo Rossi Menezes, Cristina Marta Del-Ben, Barnaby Nelson, Anita Riecher-Rössler, Rodrigo Bressan, Neus Barrantes-Vidal, Marie-Odile Krebs, Merete Nordentoft, Stephan Ruhrmann, Gabriele Sachs, Bart P.F. Rutten, Jim van Os, Eva Velthorst, Lieuwe de Haan, Maria Calem, Stefania Tognin, Gemma Modinos, Sara Pisani, Tamar C. Kraan, Daniella S. van Dam, Nadine Burger, Patrick McGorry, G. Paul Amminger, Athena Politis, Joanne Goodall, Stefan Borgwardt, Erich Studerus, Ary Gadelha, Elisa Brietzke, Graccielle Asevedo, Elson Asevedo, Andre Zugman, Tecelli Domínguez-Martínez, Manel Monsonet, Lidia Hinojosa, Paula Cristóbal-Narváez, Anna Racioppi, Thomas R. Kwapil, Mathilde Kazes, Claire Daban, Julie Bourgin, Olivier Gay, Célia Mam-Lam-Fook, Dorte Nordholm, Lasse Randers, Kristine Krakauer, Louise Birkedal Glenthøj, Birte Glenthøj, Dominika Gebhard, Julia Arnhold, Joachim Klosterkötter, Iris Lasser, Bernadette Winklbaur, Philippe A. Delespaul, Graduate School, Adult Psychiatry, Amsterdam Neuroscience - Mood, Anxiety, Psychosis, Stress & Sleep, APH - Mental Health, Amsterdam Neuroscience - Complex Trait Genetics, Amsterdam Neuroscience - Compulsivity, Impulsivity & Attention, Institut Pascal (IP), Centre National de la Recherche Scientifique (CNRS)-Université Clermont Auvergne (UCA)-Institut national polytechnique Clermont Auvergne (INP Clermont Auvergne), Université Clermont Auvergne (UCA)-Université Clermont Auvergne (UCA), Berendsen S., Kapitein P., Schirmbeck F., van Tricht M.J., McGuire P., Morgan C., Gayer-Anderson C., Kempton M.J., Valmaggia L., Quattrone D., di Forti M., van der Gaag M., Kirkbride J.B., Jongsma H.E., Jones P.B., Parellada M., Arango C., Arrojo M., Bernardo M., Sanjuan J., Santos J.L., Szoke A., Tortelli A., Llorca P.-M., Tarricone I., Tripoli G., Ferraro L., La Cascia C., Lasalvia A., Tosato S., Menezes P.R., Del-Ben C.M., Nelson B., Riecher-Rossler A., Bressan R., Barrantes-Vidal N., Krebs M.-O., Nordentoft M., Ruhrmann S., Sachs G., Rutten B.P.F., van Os J., Velthorst E., de Haan L., Calem M., Tognin S., Modinos G., Pisani S., Kraan T.C., van Dam D.S., Burger N., McGorry P., Amminger G.P., Politis A., Goodall J., Borgwardt S., Studerus E., Gadelha A., Brietzke E., Asevedo G., Asevedo E., Zugman A., Dominguez-Martinez T., Monsonet M., Hinojosa L., Cristobal-Narvaez P., Racioppi A., Kwapil T.R., Kazes M., Daban C., Bourgin J., Gay O., Mam-Lam-Fook C., Nordholm D., Randers L., Krakauer K., Glenthoj L.B., Glenthoj B., Gebhard D., Arnhold J., Klosterkotter J., Lasser I., Winklbaur B., Delespaul P.A., RS: MHeNs - R3 - Neuroscience, Psychiatrie & Neuropsychologie, MUMC+: MA Psychiatrie (3), RS: MHeNs - R2 - Mental Health, and MUMC+: Hersen en Zenuw Centrum (3)

Subjects
Research design, Psychosis, INFORMATION, IMPACT, Applied psychology, MEDLINE, Assessor selection, Pre-training inter-rater reliability, Psychosis instruments, 03 medical and health sciences, 0302 clinical medicine, Medicine, Humans, Biological Psychiatry, ComputingMilieux_MISCELLANEOUS, Observer Variation, REPRODUTIBILIDADE DE RESULTADOS, business.industry, Pre-training inter-rater reliability, Reproducibility of Results, medicine.disease, 030227 psychiatry, Psychiatry and Mental health, Inter-rater reliability, Assessor selection, TRIALS, Psychotic Disorders, Research Design, [SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC], MEASUREMENT ERROR, business, Observer variation, 030217 neurology & neurosurgery, Psychosis instruments
Abstract

International audience

Published
2019

41. Early Parental Death and Risk of Psychosis in Offspring: A Six-Country Case-Control Study

Author

Misra, Supriya, Gelaye, Bizu, Koenen, Karestan C, Williams, David R, Borba, Christina PC, Quattrone, Diego, Di Forti, Marta, La Cascia, Caterina, La Barbera, Daniele, Tarricone, Ilaria, Berardi, Domenico, Szöke, Andrei, Arango, Celso, Tortelli, Andrea, De Haan, Lieuwe, Velthorst, Eva, Bobes, Julio, Bernardo, Miguel, Sanjuán, Julio, Santos, Jose Luis, Arrojo, Manuel, Del-Ben, Cristina Marta, Menezes, Paulo Rossi, Selten, Jean-Paul, Jones, Peter B, Kirkbride, James B, EU-GEI WP2 Group, Rutten, Bart PF, Van Os, Jim, Murray, Robin M, Gayer-Anderson, Charlotte, Morgan, Craig, Misra S., Gelaye B., Koenen K.C., Williams D.R., Borba C.P.C., Quattrone D., Di Forti M., La Cascia C., La Barbera D., Tarricone I., Berardi D., Szoke A., Arango C., Tortelli A., de Haan L., Velthorst E., Bobes J., Bernardo M., Sanjuan J., Santos J.L., Arrojo M., Del-Ben C.M., Menezes P.R., Selten J.-P., Jones P.B., Kirkbride J.B., Rutten B.P.F., Os J., Murray R.M., Gayer-Anderson C., Morgan C., Supriya Misra, Bizu Gelaye, Karestan C. Koenen, David R. Williams, Christina P.C. Borba, Diego Quattrone, Marta Di Forti, Caterina La Cascia, Daniele La Barbera, Ilaria Tarricone, Domenico Berardi, Andrei Szöke, Celso Arango, Andrea Tortelli, Lieuwe de Haan, Eva Velthorst, Julio Bobes, Miguel Bernardo, Julio Sanjuán, Jose Luis Santos, Manuel Arrojo, Cristina Marta Del-Ben, Paulo Rossi Menezes, Jean-Paul Selten, Peter B. Jones, James B. Kirkbride, EU-GEI WP2 Group, Bart P.F. Rutten, Jim van Os, Robin M. Murray, Charlotte Gayer-Anderson, Craig Morgan, Misra, Supriya [0000-0003-0389-1227], Quattrone, Diego [0000-0002-6051-8309], Bobes, Julio [0000-0003-2187-4033], Bernardo, Miguel [0000-0001-8748-6717], Menezes, Paulo Rossi [0000-0001-6330-3314], Kirkbride, James B [0000-0003-3401-0824], Murray, Robin M [0000-0003-0829-0519], Apollo - University of Cambridge Repository, Psychiatrie & Neuropsychologie, MUMC+: MA Psychiatrie (3), RS: MHeNs - R3 - Neuroscience, RS: MHeNs - R2 - Mental Health, MUMC+: Hersen en Zenuw Centrum (3), APH - Mental Health, Amsterdam Neuroscience - Mood, Anxiety, Psychosis, Stress & Sleep, and Adult Psychiatry

Subjects
ESTUDO DE CASO, STRESS, CHILDHOOD, lcsh:Medicine, childhood adversities, psychosi, Parental Death, 0302 clinical medicine, Psicosi en els infants, Settore MED/48 -Scienze Infermierist. e Tecn. Neuro-Psichiatriche e Riabilitat, Medicine, early parental death, psychosis, Dol, RACE, General Medicine, Infants Salut mental, childhood adversitie, Esquizofrènia, Maternal death, HEALTH, case-control, early bereavement, DISORDERS, Offspring, DISADVANTAGE, ethnic minorities, ethnic minoritie, Article, Odds, 03 medical and health sciences, BEREAVEMENT, Journal Article, Mortalitat, Psiquiatria, Mortality, Risk factor, Settore MED/25 - Psichiatria, METAANALYSIS, multi-country, business.industry, MORTALITY, lcsh:R, Case-control study, Odds ratio, medicine.disease, Confidence interval, 030227 psychiatry, population-based, schizophrenia, Psychoses in children, business, 030217 neurology & neurosurgery, Bereavement, Demography
Abstract

Evidence for early parental death as a risk factor for psychosis in offspring is inconclusive. We analyzed data from a six-country, case-control study to examine the associations of early parental death, type of death (maternal, paternal, both), and child’s age at death with psychosis, both overall and by ethnic group. In fully adjusted multivariable mixed-effects logistic regression models, experiencing early parental death was associated with 1.54-fold greater odds of psychosis (95% confidence interval (CI): 1.23, 1.92). Experiencing maternal death had 2.27-fold greater odds (95% CI: 1.18, 4.37), paternal death had 1.14-fold greater odds (95% CI: 0.79, 1.64), and both deaths had 4.42-fold greater odds (95% CI: 2.57, 7.60) of psychosis compared with no early parental death. Experiencing parental death between 11 and 16 years of age had 2.03-fold greater odds of psychosis than experiencing it before five years of age (95% CI: 1.02, 4.04). In stratified analyses, experiencing the death of both parents had 9.22-fold greater odds of psychosis among minority ethnic groups (95% CI: 2.02−28.02) and no elevated odds among the ethnic majority (odds ratio (OR): 0.96; 95% CI: 0.10−8.97), which could be due in part to the higher prevalence of early parental death among minority ethnic groups but should be interpreted cautiously given the wide confidence intervals.

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results